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Abstract 
Following a diagnosis of cancer, patients are often faced with important medical 
decisions regarding their treatment. This decision-making process can be difficult as patients 
may not receive sufficient information about their options or may struggle to interpret the 
information they do receive. An unsatisfactory decision may lead to later decisional regret, 
which has been linked to a lower quality of life in survivors. While some research has begun 
to explore the factors that influence decisional regret, few studies have comprehensively 
examined the role that psychological and social factors may play in this process. The aim of 
the current project was to analyse and compare the factors associated with the emergence of 
decisional regret in cancer survivors internationally and in Ireland. 
Two studies were conducted. Study 1, a systematic review, analysed international 
literature aimed at exploring factors associated with decisional regret in 27,982 cancer 
patients and survivors. Study 2, a survey, explored factors associated with regret in 92 cancer 
survivors in Ireland (the majority who were breast and prostate cancer survivors). In this 
study, sociodemographic, health, psychological and social support information was analysed 
in its ability to predict regret as measured by the Decision Regret Scale. Public and patient 
involvement was used to aid the interpretation of the findings. 
In Study 1, regret in cancer patients/survivors was associated with various socio-
demographic factors, poorer physical health, a number of treatment types, an unsatisfactory 
decision-making process, poorer mental health and lack of social support. More generally, 
these factors were grouped into those which were modifiable and less modifiable from the 
patient’s perspective. These results were mirrored in Study 2, with better physical and 
psychological well-being, higher levels of shared-decision making and resilience being the 3 
factors which most strongly predicted regret. 
xi 
 
While regret was low amongst survivors, results highlight the many factors which 
may have an effect on the emergence of regret in oncology populations. As regret can be an 
obstacle to full-recovery from cancer, researchers and health-care professionals should 
continue to work towards better methods of identifying patients most at risk of experiencing 
regret as well as methods of mitigating the emergence of this negative phenomenon.
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Chapter 1 
General Introduction
2 
1.1 Introduction 
Cancer is a disease known by all and experienced by many. While the search for a 
cure continues, there are a number of treatment options that patients may avail of, including 
surgery, radiation therapy, chemotherapy and hormone therapy. In many cases, more than one 
treatment type is available, leaving the patient with a difficult decision to make.  As discussed 
below, this decision can lead to decisional-regret which in turn may lead to lower quality of 
life, long after treatment has ceased. Unfortunately, the long-term well-being of cancer 
survivors is often overlooked as they may be left with little valuable support after receiving 
the ‘all-clear’ (Owen, Goldstein, Lee, Breen & Rowland, 2007; Shroevers, Helgeson, 
Sanderman, & Ranchor, 2010).  
This thesis aims to explore the experience of treatment-related regret and decision 
making in cancer survivors in more detail. Understanding the factors which can lead to this 
experience is merited so that health care professionals may be in a position to reduce the 
likelihood of regret as survivors navigate the disease trajectory. In this chapter, the concepts 
of treatment decision making and regret are introduced prior to presenting a more detailed 
overview of the aims and objectives of the current project 
1.2 Cancer Survivorship 
The most recent report published by the National Cancer Registry (2018) shows that 
cancer cases in Ireland are on the rise and that they may double by 2045. It was estimated that 
over 200,000 people were living with or beyond cancer in 2019 in Ireland alone, with 40,000 
people receiving a diagnosis each year (O’Connor, O’Donovan, Drummond, & Donnelly, 
2019).  Worldwide, there were 17 million new cases of cancer in 2018, with the most 
commonly diagnosed cancers being lung, female breast, bowel and prostate cancer (Cancer 
Research UK, 2019). Advances in cancer detection and a wider range of treatment options 
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have also resulted in an increasing numbers of cancer survivors, with breast and prostate 
cancer survivors making up most of survivors living in Ireland (O’Connor et al., 2019).  
 With more survivors comes the need for a general understanding of the supports that 
would be of most benefit for patients not only during the illness and treatment, but also after. 
Physical and psychological side effects of cancer and/or treatment may affect survivors long 
after treatment has been completed (Brydøy et al., 2009; Mao et al., 2013; Monje & Dietrich, 
2012; O’Connor et al., 2019). Furthermore, psychosocial side effects are common as cancer 
survivors may report decreases in their quality of life which can occur as a result of changes 
associated with their ability to take part in previously normal activities such as self-care, 
work, hobbies, or family life (Carelle et al., 2002). A need for greater access to support 
services, sexuality related needs, as well as information, have also been reported by Irish 
cancer survivors (O’Connor et al., 2019). This suggests that efforts are needed to be made to 
provide continued support for survivors. One area in which patients may benefit from support 
is in the area of treatment decision making, discussed in more detail below. 
1.3 Treatment Decision Making 
1.3.1 Types of Treatment Decision Making 
The choice of cancer treatment can have considerable consequences for patients 
whose future well-being, often extending to that in later survivorship, depends on this 
decision. While not all cancer treatments are preference sensitive, in many cases there may be 
different options available for patients and clinicians. For example, prostate cancer treatment 
may involve surgery (prostatectomy), radiation therapy, brachytherapy or hormonotherapy 
(Pearlstein, Basak, & Chen, 2019). While these treatments may be similar in terms of their 
clinical efficacy, the outcomes can result in different side effects for patients and they may 
need to be considered as part of the decision-making process.  
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Decision making in health care settings can take many different forms depending on 
the role that the patient and health care professional (HCP) play in this process. This can 
include shared decision making (SDM) which is currently a popular approach (Cahill, Zilidis, 
& Grundy, 2018; Driever, Stiggelbout, & Brand, 2020), as well as autonomous decision 
making (also referred to as patient-centred), which contrast with the more traditional 
paternalistic approach (Lepping, Palmstierna, & Raveesh, 2016).  
The paternalistic approach refers to acts of authority by the physician in directing care 
and in the distribution of resources to patients (Sandman & Munthe, 2010). The patient’s 
wishes and choices are not respected in this type of decision making. It has been described as 
acting for the good of the patient, without the patient’s will (Groll, 2014a), and has been less 
favoured in recent years as it disregards patient autonomy. The paternalistic approach does 
not treat patients as knowledgeable enough about their condition and typically ignores the 
patients’ opinions, thoughts and feelings (Sandman & Munthe, 2010). However, an argument 
can be made for some use of paternalism when patient autonomy is not possible, and when 
the principle of benefiting the patient is prioritised in the HCP’s decision-making process 
(Groll, 2014b; Roeland et al., 2014). 
In contrast, the patient-centred approach respects patient autonomy, which is the 
ability of a person to make their own decision without the health care provider influencing 
them (Lepping, & Raveesh, 2014). Patient autonomy allows for the physician to educate the 
patient but not to decide for the patient. The growth in popularity of this approach has pushed 
clinicians towards the assessment of decision making preferences of their patients and the 
facilitation of independent decision making with appropriate information provision (Ahmed 
et al., 2018; Rodriguez-Osorio & Domingue-Cherit, 2008). While this approach may be more 
preferable than the paternalistic approach, studies show that many patients prefer to give up 
5 
complete autonomy in decision making in favour of the SDM approach (Deber, Kraetschmer, 
Urowitz, & Sharpe, 2007). 
In SDM, both the patient and physician contribute to the medical decision-making 
process (Fried, 2016; Hargraves, LeBlanc, Shah, & Montori, 2016). Typically, the physician 
shares the relevant risks and benefits of all treatment alternatives with the patient, while the 
patient shares relevant personal information that might make one treatment or side effect 
more or less tolerable than others with the physician. Both parties use the shared information 
to come to a mutual medical decision. This decision making approach has become the topic 
of research interest in recent years due to the belief that it allows patients to receive care 
which is right for them, therefore reducing medical errors and improving post-treatment 
satisfaction (Brodney, Fiwler, Wexler, & Bowen, 2016; Vercellini et al., 2018). 
More recently, decision making in health care settings has been changed by advances 
in medicine and technology (Salvador et al., 2017; Sun, 2017; Voena & Chiarle, 2016). 
Notably, clinical advances have resulted in more treatment options available, which may put 
pressure on the patient’s decision making process, especially if they feel uninformed or are 
lacking the required health literacy (Erlen, 2004). However, advances have also led to 
positive developments. For example, decision aids have transformed decision making in 
health care by allowing patients to better understand the number of treatment options 
available, their risks, benefits, and costs (Leighl et al., 2011). Many studies find that the use 
of a decision aid results in more post-treatment satisfaction and less post-treatment regret in 
patients (Brooks et al., 2019; Søndergaard et al., 2019). Decision aids are now widely used to 
facilitate the SDM approach (Spatz, Krumholtz, & Moulton, 2017). 
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1.3.2 Theoretical Approaches to Understanding Decision Making Preferences  
Studies show that people’s preferences around decision making strategies vary 
substantially and that while SDM is a popular choice it is not favoured universally (Deber et 
al., 2007; Deucher et al., 2016; Rodriguez-Osorio & Dominguez-Cherit, 2008). Some suggest 
that more research into the SDM strategy is needed (King & Moulton, 2006), especially since 
there is a lack of guidance about how to achieve it (Elwyn et al., 2012; Légaré et al., 2010). 
Other studies show that many patients prefer to leave the decision completely up to their 
physician, i.e., paternalistic decision making (Arora & McHorney, 2000).  
Traditional theories of decision making may explain people’s preferences of 
involvement. For example, Ritov and Baron (1995; 2004) describe how the phenomenon of 
omission bias can influence decision making. According to the researchers, this bias comes 
from people’s preference to choose no action rather than action (Brewer, DeFranklin, & 
Gilkey, 2016). For example, Ritov and Baron (1995) found that subjects were reluctant to 
vaccinate their children if they were told that there was a possibility of death resulting from 
the vaccination, even if this occurrence is much less likely than death caused by the disease 
prevented by the vaccination. This may explain why some patients decide to leave the 
decision up to the physician, as transferring the action onto someone else releases the patient 
of responsibility for consequences.  
Patient avoidance of action may also be explained by the involvement of emotion in 
decision making. Our everyday life experiences leave no doubt that emotion impacts our 
decision making (cancer diagnosis is undoubtedly an emotional experience) (Lakomski & 
Evers, 2010; Lerner, Li, Valdesolo, Kassam, 2015; Morrice, 2013), and that the consequences 
emerging from our decisions can influence our emotions (Schwarz, 2000). There is an 
influence of emotion on avoidance of action and the key emotions involved in this process 
7 
are anticipated regret and fear (Anderson 2003). The experience of regret is elaborated on in 
section 1.4. 
Of course, while some patients may prefer not be involved in decision making, other 
studies find that many patients do want to be informed and involved where possible (Brom et 
al., 2014; Chewning et al., 2012; Guadangoli & Ward, 1998). However, patient involvement 
may not always lead to a satisfactory treatment choice, partly as humans can find it difficult 
to make fully rational decisions.  
An early theory of decision making which assumed that people are rational as they 
choose between uncertain options by examining the utility of each option and logically 
considering the probability of that option occurring (Mongin, 1997; Schoemaker, 1982), has 
been disproved (Dhami & al-Nowaihi, 2006). Instead of basing decisions on a rational 
calculation, our decisions are instead formed by our risk-aversive nature in respect to gains, 
and risk-acceptant nature in respect to losses (Breen, van de Werfhorst, & Jæger, 2014). 
When deciding, we prefer not to lose rather than to gain. For example, it has been shown that 
participants incorrectly predict their level of happiness to decrease significantly after a loss 
than to rise after a gain (Kermer, Driver-Linn, Wilson, & Gilbert, 2006).  
When presenting treatment-related information, physicians tend to present the risk 
and benefits side-by-side, giving patients a fair opportunity to see both the possible benefits 
and side-effects of each choice (Oussedik, Anderson, & Feldman, 2017). The patients’ risk 
aversive nature however may lead towards the risk being weighed more heavily than the 
benefit, resulting to poor and irrational treatment choices (Oussedik et al., 2017). In order to 
avoid this, physicians may present the risk of choosing a treatment against the risk of not 
choosing it (Oussedik et al., 2017). This is the guiding principle behind decision aids – to 
present risk and benefits of choosing (or not choosing) various treatments. 
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Several other studies find that patients want to be asked their opinion but wish to 
leave the final decision to the medical experts (Levinson, Kao, Kuby, & Thisted, 2005; 
Schoenfeld et al., 2018). These results have encouraged research on matching patient 
participation level preferences with the decision making process as this results in more 
satisfaction and less regret post-treatment (Brom et al., 2014; Brown et al., 2012; Kiesler & 
Auerbach, 2006; Robinson & Thompson, 2001).  
As detailed above, traditional theories of decision making can aid understanding of 
this process in a healthcare setting and show why patients may or may not want to be 
involved. Recent studies show the vast number of factors that may affect decision making, 
including an individual’s socio-demographic characteristics, their psychological appraisals 
and the amount of support they receive during the decision-making process (Dias-Ferreira, 
2009). For instance, an individual’s age, gender, level of education, marital status and socio-
economic status may affect decision making styles (Hubbard, Kidd, & Donaghy, 2008; 
Schneider et al., 2006). This implies that decision making is a complex process and the 
outcomes may be guided by a multitude of complex factors. 
It is important to note that most studies on decision making practices and patient 
preferences have been conducted outside of Ireland, aside from some studies conducted, for 
example, in collaboration with the National Cancer Registry of Ireland (NCRI) (Sharp et al., 
2013). Also, these studies have tended to focus on one cancer type in isolation (e.g. prostate 
or breast cancer), rather than cancer types more generally. The current project aims to address 
this gap as well as more specifically focusing on one particular consequence of decision 
making, that is regret (discussed in more detail below).  
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1.4 Regret 
1.4.1 Definitions of Decisional Regret 
Most decisions have consequences, and cancer treatment decisions have consequences 
which can affect the well-being and quality of life of patients long post-treatment. One 
negative consequence which very often appears in studies of cancer treatment is the 
experience of regret (Albkri et al., 2018; Flitcroft, Brennan, & Spillane, 2018; Walczak & 
Velanovich, 2018).  
The feeling of regret is a common experience in many contexts, and multiple theories 
and approaches have attempted to explain this emotion more broadly. There is, however, 
some disagreement as to how this process arises. Philosophical theories have attempted to 
explain regret according to the internal state with which it is accompanied and by the 
circumstances in which it occurs. An attempt has also been made to distinguish regret from 
other similar emotions like disappointment, guilt, remorse or sadness (Gilovich & Medvec, 
1995, Kedia & Hilton, 2011). A definitional issue was found by the philosophical approach to 
regret: specifically, can a person say that they regret something if they would hypothetically 
do it again? (Gilovich & Medvec, 1995). According to Hampshire (1960), such a feeling 
could be described as anxiety, guilt or a wish to have been placed in different circumstances, 
but it cannot be said to be regret. According to Gilovich and Medvec (1995) however, this 
view of regret has been disagreed with by many scholars as it is possible to think of examples 
of actions which people have regretted but were forced to repeat it in order to reach a goal.  
The economic approach to understanding regret proposes that people will sacrifice 
monetary gain in order to avoid subsequent regret (Gilovich & Medvec, 1995; Martinez & 
Zeelenberg, 2015). This suggests that people are subconsciously aware of the negative effects 
that regret may have on them. Several studies show that anticipated regret affects our choices 
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(Hetts, Boninger, Armor, Gleicher, & Nathanson, 2000; McCormack & Feeney, 2015; 
Wright & Ayton, 2005). However, Gilovich and Medvec (1995) find that economical 
theorists’ definition of regret is too narrow as it includes the difference between the value of 
the chosen option versus other alternatives, but it does not consider the path by which an 
option was decided (this too can affect regret). 
Research on counterfactual thinking has also added to our understanding of regret and 
why it occurs. Counterfactual thinking involves thoughts about alternatives to past events. 
These thoughts can regulate behaviour and our emotional response to past events (Epstude & 
Roese, 2008; Medvec, Madey, & Gilovich, 1995). Engaging in counterfactual thinking has 
been found to evoke negative emotions like dissatisfaction, envy, distress and most notably 
regret (Baron, 2000; Broomhall, Phillips, Hine, & Loi, 2017; Zeelenberg et al., 1998). 
Research on counterfactual thinking has addressed the problems found with the economic 
approach. This approach is concerned with people’s imagined alternatives to their choice, and 
unlike in the economic approach regret is not seen to be tied to known outcomes only 
(Coricelli & Rustichini, 2010). The counterfactual thinking approach also sees the path by 
which a decision was made as an important part of the emergence of regret. Different paths 
may lead to the same outcome and their counterfactual consideration may lead to different 
levels of regret (Epstude & Jonas, 2015). Unlike in the economic approach, this research does 
not consider regret to be tied to the outcome of the decision in isolation to other factors.  
The Decision Justification Theory (Connolly & Zeelenber, 2002) suggests that 
decision related regret has two main components, which can occur in isolation or 
simultaneously: the outcome of the decision and the self-blame for the choice made. When 
regret occurs due to the combination of both, a person regrets the ‘incorrect’ decision made 
and blames themselves for doing so (Connoly & Zeelenber, 2002). However, a person may 
be happy with the outcome of their decision, and still feel self-blame, Connolly and 
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Zeelenber (2002) provide an example of a drunk driver arriving home safely – the driver 
accepts that their decision had a good outcome but feel self-blame as they imagine what 
could have happened. A well thought-out decision which results in bad consequences may 
result in regret due to unwanted outcomes, but self-blame may not be present as a person 
understands they did everything they could to make an informed choice, e.g., a parent whose 
child’s well-researched vaccination against a deadly disease results in unwanted side effects 
(Connolly & Zeelenber, 2002). The theory provides an interesting explanation as to why 
regret may occur in those both those who take responsibility for a decision and those who do 
not, as well as those who are satisfied with the outcome of their decision and those who are 
not. 
Theoretical approaches to understanding regret can provide some insight into what 
gives rise to this experience. A drawback of much empirical research in this area however is 
that it tends to focus on hypothetical scenarios rather than real-world decision-making. The 
study of regret in health-related contexts can give a more in-depth understanding of regret in 
practice. 
1.4.2 Regret in Cancer Survivors 
Regret is reported by those who feel they made an inappropriate choice, or by those 
who failed to do something they feel should have been done for a better outcome. The 
healthcare setting is filled with situations which put both health care professionals and their 
patients under pressure to make decisions, especially decisions about treatments. For this 
reason, regret is commonly studied in relation to treatment decision making across various 
patient groups (Advani et al., 2019; Holmes et al., 2017; Tanno & Bito, 2019). Regret can be 
described as occurring in three contexts here: outcome regret – regret which comes from the 
outcome of a decision, option regret – regret stemming from the alternative chosen, and 
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process regret – regret linked to the way in which the decision was made (Connolly & Reb, 
2005). All three types of regret may be experienced at once, individually or in different 
combinations. For example, a patient may regret the treatment decision-making process but 
not the actual treatment chosen or its outcomes (Connolly & Reb, 2005). 
Cancer patients are the most widely researched population by researchers of regret 
post treatment (Cuypers et al., 2019; Peterson et al., 2019; Windon et al., 2019). This is likely 
due to the vast amount of treatment options available to cancer patients and, as mentioned 
above, the more treatment options available, the bigger the possibility for regret (Chernev, 
Böckenholt, & Goodman, 2015). Recent research however suggests that the prevalence of 
regret in cancer patients is surprisingly low considering the amount of treatment choices often 
available (Lee & Knobf, 2015; Martinez et al., 2015; Shakespeare et al., 2017). Despite this, 
regret in cancer patients and survivors remains an important topic for researchers, especially 
given its known relationship with lower QoL post-treatment and throughout survivorship 
(Albkri et al., 2018; Clark, Ray, Ashton, 2001; Diefenbach, Mohamed, Horwitz, & Pollack, 
2008; Hu et al., 2008). Understanding how best to mitigate later regret in individuals with 
cancer is an important aspect of the quest to fulfil the needs of both cancer patients and 
survivors.  
Regret post-cancer treatment may occur for many reasons and has commonly been 
found in patients who experienced: lower sexual functioning post-treatment (Davidson, So, & 
Goldenberg, 2007; Diefenbach & Mohamed, 2007; Rattcliff, Cohen, Pettaway, & Parker, 
2013; Christie, Sharpley, & Bitsika, 2015), a decrease in role and social functioning 
(Davidson et al., 2007), increased pain (Davidson et al., 2007), disease-specific side effects 
(e.g., urinary dysfunction) (Diefenbach & Mohamed, 2007; Christie et al., 2015), high 
expectations of treatment which were not reached (Schroeck et al., 2008), low satisfaction 
with preparatory information (Sheehan, Sherman, Lam, & Boyages, 2007), or a longer time 
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since treatment (Christie et al., 2015; Hu et al., 2008), amongst others. In addition, a range of 
socioeconomic factors may be associated with regret, for example financial difficulty 
(Davidson et al., 2007; Lee & Knobf, 2015). It is important to note that most studies 
mentioned have focused on prostate cancer patients, with less known about influences of 
regret in other cancer types. More research on the factors which are linked to regret post-
treatment in different types of cancers is needed. 
 As discussed above, regret may be described in three contexts and it is not always 
associated with the treatment chosen. It has been shown that the path to the decision also 
influences the emergence of regret. Unsatisfactory levels of involvement in the decision-
making by the patient, or a low level of understanding of the medical information at the time 
of the decision have been linked with the emergence of decisional regret (Davidson et al., 
2007; Hack, Degner, & Watson, 2006; Mancini et al., 2012). Insufficient time may also play 
a role in a rushed decision making process and a later emergence of regret (Shepherd, 
Tattersall, & Butow, 2008). As discussed above, people experience more regret from negative 
outcomes stemming from action, rather than the same negative outcomes coming from 
inaction (Gilovich & Medvec, 1995; Chapman & Coup, 2006). An unsatisfactory level of 
involvement does not necessarily mean that the patient wanted to be more involved than they 
were. Sometimes, due to negative consequences of the treatment, the patient may feel like 
they should have stepped aside and let the physician make the decision instead. This, 
however, is rare. Even though we often feel like action produces more regret than inaction 
(Kahneman & Tversky, 1982) and regrettable actions are troubling, it seems that regrettable 
failure to act causes more regret in real-life situations (Gilovich & Medvec, 1995). 
There have been attempts made to mitigate decisional regret in various patient 
populations with the use of decision aids, some being very successful (Knops, Legemate, 
Goossens, Bossuyt, & Ubbink, 2013). Many of these aids concentrate on increasing patient 
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participation in the decision making and ensuring a greater understanding of the medical 
information (Gaston & Mitchell, 2005; Kennedy et al., 2012; O’Connor et al., 1999). 
However, greater involvement in decision making does not always lead to less regret post-
treatment. Furthermore, decisional regret does not always occur simply due to an 
inappropriate level of patient involvement or understanding. There are a number of other 
factors that may need to be considered. 
1.5 Limitations of Current Research 
Emerging research is adding to a greater understanding of the importance of decision 
making aids in the mitigation of decisional regret in patients. However, most of the studies 
conducted concern themselves with cancer patients only, and rarely with long-term cancer 
survivors. This limits our knowledge of the emergence of decision regret at different time 
points. More specifically, the vast amount of these studies are concerned with prostate cancer 
(Chien, Chuang, Liu, Li, & Liu, 2014; Davidson & Goldenberg, 2003; Diefenbach & 
Mohamed, 2007) and breast cancer patients (Andersen, Bowen, Morea, Stein, & Baker, 2009; 
Hack et al., 2006; Sawka et al., 1998; Sheehan et al., 2007). There is a lack of work 
conducted with other cancer patients, or with the general cancer patient population to 
establish whether there are any trends in the experience or regret. This problem is worthy of 
investigation, as other forms of cancer can also be treated by different means (e.g., head and 
neck cancer, liver cancer, skin cancer, etc.), and a decision on the type of treatment is 
required. In other words, other cancer patients may also experience regret and it is worth 
exploring experiences across various groups. In addition, while a good deal of work has 
explored how aspects of the decision making process may impact regret, less research has 
explored how a range of sociodemographic, psychological and social factors may influence 
this experience and relatively little research has been conducted on this topic in an Irish 
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context. Detailed considerations of such issues may be helpful in informing the development 
of interventions aimed to reduce the likelihood of later regret. 
1.6 The Current Study 
1.6.1 Aims and Objectives of the Current Research 
 The current research aims to explore the factors which have been found to be 
associated with the emergence of decisional regret in cancer patients and survivors. This will 
be achieved by two studies. Study 1 is a systematic review of existing literature in the area, 
while Study 2 involves an exploration of the decision making experiences and prevalence of 
regret in a sample of cancer survivors living in Ireland.  
In the following chapters, these studies and their findings will be described in more 
detail. Chapter 2 describes study 1, which reviews research on different cancer survivors in 
order to achieve a better understanding of those who are most prone to experience regret 
post-treatment. The methodology for study 2, which aims to explore the factors associated 
with the emergence of decisional regret in Irish cancer survivors, is described in Chapter 3, 
with results described in Chapter 4. In discussing the results of this study (Chapter 5), 
findings will be compared to those from study 1, the systematic review, in order to 
investigate the similarities and/or differences associated with the emergence of regret 
between Irish cancer patients and the international literature. Finally, using public and patient 
involvement (PPI) Chapter 6 describes how the results of both studies may inform 
interventions concerned with the wellbeing of cancer survivors, and particularly those living 
in Ireland. 
1.6.2 Chapter Summary 
This chapter has reviewed theoretical approaches to understanding treatment decision 
making and regret. Research points to an association between certain aspects of cancer 
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treatment decision making and the emergence of decisional regret. More specifically, the 
research described here discusses the association between regret and the level of patient 
involvement in the treatment decision making process. While literature suggests that this is a 
common reason for the emergence of regret in cancer patients/survivors, it is not the only 
one. Alternative studies of various cancer patients may uncover more specific factors linked 
to the emergence of regret and suggest that it is not enough to simply attribute the treatment 
type chosen for regretful feelings to occur. A detailed analysis of the different factors found 
by studies conducted world-wide with various cancer patients will be discussed in the 
systematic review in Chapter 2. 
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Chapter 2 
A Systematic Review of the Factors Associated with Regret Post-cancer Treatment
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2.1 Overview 
The literature reviewed in the previous chapter highlighted that there are many 
possible reasons for the emergence of decisional regret in cancer patients and survivors. 
Factors associated with regret may include survivor psychological, socio-demographic and 
health-related characteristics. In order to gain more insight into the emergence of decisional 
regret in those with cancer diagnoses, this chapter describes a systematic review investigating 
the factors associated with the experience of regret in a range of cancer survivors  
2.2 Background and rationale 
A diagnosis of cancer is understood to not only affect individuals during the illness or 
treatment period, but also during survivorship. The feeling of regret has been found to impact 
cancer patients and survivors negatively (Davidson, So, & Goldberg, 2007; Diefenbach & 
Mohamed, 2007). As outlined in chapter 1, regret has been defined as a negative feeling or 
emotion, which is associated with thinking about a past event or choice (Connolly & Reb, 
2005). With many studies now focusing on this phenomenon (Benedict; Thom, & Kelvin, 
2015; Christie, Sharpley, & Bitsika, 2015; Fernandes-Taylor & Bloom, 2011), we are 
beginning to understand exactly what individuals regret about their treatment, but also about 
other aspects of their experience while ill. In healthcare settings regret can occur in three 
main contexts: outcome regret – regret which comes from the outcome of a decision, option 
regret – regret stemming from the alternative chosen, and process regret – regret linked to the 
way in which the decision was made (Connolly & Reb, 2005). All three types of regret may 
be experienced at once, individually or in different combinations (Connolly & Reb, 2005). 
For example, a patient may regret the treatment decision-making process but not the actual 
treatment chosen or its outcomes Quite often, it is found that the specific treatment type 
chosen is the cause of regret in cancer patients (Ratcliff, Cohen, Pettaway, & Parker, 2013). 
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For example, cancer treatment generates most reports of regret in medicine, more than 
clinical trials and prophylactic breast surgery (Sawka et al., 2012, as cited in Christie et al., 
2015).  
The literature reviewed in the previous chapter showed that regret may be linked to 
the level of patient involvement in the decision making process. However, studies have found 
many other factors which may be associated with regret. It is important to note that this 
association does not imply causation. Nevertheless, studies of this nature allow for a clearer 
understanding of the environment in which decisional regret may occur in cancer 
patients/survivors. An individual’s ethnicity, age, psychological well-being, education-level, 
or income-level are all factors, amongst many others, which have been found to be associated 
with this phenomenon. However, more research is needed to fully understand this complex 
process. 
A number of systematic reviews analysing studies of regret in cancer patients have 
been conducted (Christie, et al., 2015; Flitcroft, Brennan, & Spillane, 2018; Wilson, 
Ronnekleiv-Kelly, & Pawlik, 2017). The findings of these reviews suggest a broad spectrum 
of factors associated with regret, e.g., sexual and urinary function, age or longer time since 
treatment (Christie et al., 2015), unclear nature of information provided to patients, 
depression, distress or negative body image (Flitcroft et al., 2018), type of surgery, disease-
specific quality of life or shared decision making (Wilson et al., 2017). However, these 
reviews often have very narrow inclusion criteria, allowing for studies concentrating on one 
cancer type or one treatment type only. This systematic review aims to analyse studies of 
cancer regret in patients and survivors of all cancer types in order to create a broader 
overview of the challenges faced by cancer patients before, during and after various treatment 
types. It is important to understand the common experiences of survivors to enable the 
provision of supports for this group, and to identify those most at risk of experiencing regret. 
20 
2.3 Objective 
The objective of this review is to provide a synthesis of evidence on the correlates of 
regret in general oncology populations across various study designs, with the intention of 
identifying potentially modifiable factors that may inform interventions tailored towards 
supporting survivors.  
2.4 Method 
2.4.1 Search Strategy for Identification of Studies 
The study was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Appendix A). Studies in 
English up to April 2019 with no restrictions on time period were searched using: Web of 
Science, PubMed, PsycINFO and EMBASE. To ensure the maximum reach, the databases 
were searched using the following free text search terms and Boolean operators: “cancer 
survivors” OR “cancer patients” AND “decision” AND “regret” OR “decisional regret”. 
These terms were selected following an investigatory search of available literature (Aning, 
Wassersug, & Goldenberg, 2012; Chien, Chuang, Liu, Li, & Liu, 2014; Goepfert et al., 2017) 
and based on their occurrence as well as their relevance to the research question. The terms 
were piloted in all of the databases used in different combinations in order to ensure the 
literature search was not limited. The reference lists of relevant articles were also checked for 
additional suitable studies. 
2.4.2 Criteria for Inclusion 
Studies included in the review were required to satisfy specific inclusion criteria, 
agreed on by two reviewers. The criteria for inclusion can be found in Table 1 below. Only 
studies in which the participants were adults were included in the review. At the time of the 
study, the participants must have been patients or survivors of any type of cancer. Data 
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collected from carers of cancer patients/survivors, relatives of cancer patients/survivors, or 
doctors was not included. The review included studies which only collected primary data 
directly from participants who had been diagnosed with cancer and which used a measure of 
decisional regret. Studies which mentioned measuring treatment regret in cancer 
patients/survivors but did not clearly state the measure used were not included. This was to 
ensure that any regret reported in association with other factors could be assessed. However, 
any study which captured a measure of regret was considered for inclusion, including self-
reported assessment, quantitative close-ended questions, open-ended questions and 
qualitative questions. Most of the studies analysed used validated measures of regret (e.g. 
Decision Regret Scale) but unvalidated measures were also considered to meet this inclusion 
criterion. Studies measuring regret about fertility preservation were not included. At least one 
factor associated with the emergence of decisional regret must have been studied for the 
article to be included in the review. This review included studies published in English. 
Studies from peer-reviewed journals were included in the review. Poster/conference abstracts 
were not included. Studies of any design type (qualitative, quantitative, mixed etc.) were 
considered for inclusion. 
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Table 1 
Systematic review inclusion and exclusion criteria 
   
Criteria       Inclusion       Exclusion 
Types of participants • Adults 
• Cancer 
patients/survivors 
• Primary data  
• Minors 
• Carers of cancer 
patients/survivors 
• Relatives of cancer 
patients/survivors 
• Health-care 
professionals  
Measurement of regret • Validated measure of 
regret used in 
quantitative studies 
• A discussion of 
regret in qualitative 
studies 
• Non-validated 
measure of regret 
used 
• Measure of regret 
used not clearly 
stated 
Regret measured in 
association with at least 
one other factor 
• Studies which 
measured the 
association between 
the emergence of 
regret and at least 
one other factor 
• Studies which 
measured regret but 
did not study the 
association between 
its emergence and 
other factors 
English language • Studies published in 
English 
• Studies not published 
in English 
Publication type • Peer-reviewed 
journal 
• Conference/ poster 
abstract 
Study Design • Any • / 
 
2.4.3 Screening Procedure 
Results from the database searches were transferred into Rayyan (Ouzzani, 
Hammady, Federowich, & Elmagarmid, 2016) an open-source web application created for 
systematic reviews. This application allowed both reviewers to have access to the articles at 
the same time, to read abstracts, mark articles as included/excluded/maybe, organise them 
into categories, leave notes and to see the decisions of the fellow researcher.  
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Titles and abstracts of articles found in the database search were first independently 
screened by both reviewers to establish whether they met the inclusion criteria. Where 
conflicts occurred, these were discussed until agreement was reached. Full texts were sourced 
for articles, which appeared to be suitable after the initial screening. This was done using the 
Maynooth University library database and Google Scholar. In some instances, the authors of 
articles were contacted with a request for a copy of the full text. Full texts were then read to 
ensure they met the inclusion criteria. A number of articles did not have full texts as the 
abstracts came from posters and conferences, thus did not meet the inclusion criteria. The 
reference lists of included studies were also screened for relevant articles but none were 
included in the final review.  
The database search returned 1747 articles, 455 of which were initially removed, as 
they were duplicates, leaving 1292 articles for the screening process. After the screening of 
the remaining titles and abstracts by the two reviewers, full texts were obtained for 156 
studies. Based on the inclusion criteria, a further 84 articles were excluded. This was mostly 
due to the lack of an appropriate measure of regret and/or no factors linked to the emergence 
of regret. The process described is further illustrated in Figure 1 below (based on the flow 
diagram of The PRISMA Group, 2019). 
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Figure 1 
PRISMA flow diagram for various phases of the systematic review 
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2.4.4 Quality Appraisal 
Methodological quality was assessed using the Mixed Methods Appraisal Tool 
(MMAT) Version 2018 (Hong et al., 2018; Pace et al., 2012; Souto et al., 2015). Two 
reviewers conducted the appraisal. Each reviewer independently assessed the quality of each 
study using a checklist (Appendix B). The individual assessments were then compared and 
any discrepancies were discussed. As per the MMAT user guide, the studies were not 
awarded points or scores. Instead, the user guide advised “to provide a more detailed 
presentation of the ratings of each criterion to better inform the quality of the included 
studies” (Hong et al., 2018, p.1). Studies of low methodological quality were not found. 
However, if studies of low quality were found, they would not have been excluded as the user 
guide discouraged this.  
Each study was categorised and assessed using seven questions: two screening 
questions and five questions relevant to the category of the study. There were three possible 
answers to each question: ‘Yes’. ‘No’ and ‘Can’t tell’. A comment section beside each 
question allowed for a justification of each answer chosen. The two screening questions (‘Are 
there clear research questions?’ and ‘Do the collected data allow to address the research 
questions?’), required a ‘Yes’ answer, which all studies in the review satisfied. Otherwise, it 
was assumed that the paper is not an empirical study and cannot be assessed using the 
MMAT. One of two ‘Yes’ answers indicated low quality, three ‘Yes’ answers indicated 
moderate quality, four or five ‘Yes’ answers indicated strong quality. All of the studies were 
found to be strong or moderate quality.  Studies of low methodological quality were not 
found suggesting a low risk of bias. 
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2.4.5 Data Extraction and Analysis 
The following information was extracted from included studies by one researcher: 
design, setting, participants, cancer type, treatment, measure of regret, prevalence of regret, 
and factors associated with regret. This information was then discussed and agreed with the 
second researcher. Results were analysed using the process of narrative synthesis, which is a 
commonly-explored approach followed by other researchers (Ngwenya et al., 2017; Scalia et 
al., 2018).  
2.5 Results 
2.5.1 Description of Studies 
After all exclusions, 72 articles were found to be of relevance to the review. Table 2 
provides details of these studies. The studies in the review involved various designs: 3 
qualitative, 12 quantitative randomized controlled trials, 53 quantitative descriptive and 4 
used mixed methods (as per MMAT categorisation). 
The studies were conducted in a range of countries: 39 in the USA, 8 in Canada, 5 in 
Australia, 3 each in Taiwan and The Netherlands, 2 each in England, Scotland, Turkey and 
China and 1 each in France, Ireland, Germany, Spain, Italy and Iran. The sample sizes ranged 
from 28 to 2,030 participants, with a total of 27,982 participants taking part in all of the 
studies combined. Most of the studies were concerned with prostate cancer (n = 42, 58.33%) 
and breast cancer (n = 20, 27.78%). However, a number of studies focused on less prevalent 
cancer types: thyroid cancer (n = 2, 2.78%), oropharyngeal carcinoma (n = 1, 1.39%), head 
and neck cancer (n = 1), colon cancer (n = 1), uveal melanoma (n = 1), colorectal cancer (n = 
1), laryngeal (n = 1) acute myeloid leukaemia (n = 1). One study involved patients suffering 
from more than one cancer type – specifically cancer patients with a tumour who underwent 
adjuvant chemotherapy.  
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Treatment types undertaken by the participants in the studies included: surgery, 
radiotherapy, hormone therapy, brachytherapy, active surveillance, endocrine therapy, 
adjuvant radioactive iodine treatment, stem cell transplant, orchiectomy, chemical castration 
and watchful waiting. Many of the studies were inclusive of a range of treatments (Cuypers et 
al., 2019), while others only allowed the inclusion of specific treatment types (Kinsella et 
al.,2012). Many studies did not provide details of the treatment type undertaken by the 
participant or provided limited information about this (Diefenbach, & Mohamed, 2007; 
Goepfert et al., 2017).  
As per the inclusion criteria, the studies in this review were required to measure 
regret. The most common tool used was the five-item Decision Regret Scale (O’Connor, 
2003; n = 39, 54.17%) followed by the two-item regret questionnaire by Clark et al (2001; n 
= 9, 12.5%). Many of the studies used adapted versions of those scales or other validated 
Likert scales (Schroeck et al., 2008). Other studies assessed regret using a single item 
question (Christie, Sharpley, Bitsika, & Christie, 2017) or, in the case of qualitative studies, 
asked participants to discuss their experience of regret, e.g., 'Looking back, is there anything 
about your treatment that you would do differently?’ (Fernandes‐Taylor, & Bloom, 2011). 
Description of all methods used can be found in Table 2. References of all studies included in 
the review can be found in Appendix C. 
Overall, the level of regret experienced by participants was low. Of the 22 studies 
reporting the percentage of regret experienced, results ranged from 0%-56% (M = 21%). Four 
additional studies reported percentages of participants experiencing low (M = 26.3%), 
moderate (M = 37.9%) or high (M = 10.5%) regret, while a single study reported percentages 
of regret experienced by participants at three time points (baseline post-treatment = 10%, 3 
months post-treatment = 17.3%, 12 months post-treatment = 10%). Ten studies reported 
regret obtained from the DRS with scores ranging from 4.9 to 22.1 (M = 14.4). A number of 
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studies however did not provide information on regret prevalence and simply discussed 
correlates of this. 
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Table 2  
Summary table of studies included 
Study 
no. 
Reference Country N  Gender Cancer  Treatment Type Measure of regret Study design Prevalence of regret 
1. Albkri et al. 
(2018).  
France 226  
 
Male Prostate  Surgery, radiotherapy, 
hormone therapy 
Single item Quantitative 
descriptive 
27.8% undecided or regretted 
choice of treatment; 69.4% did 
not regret it. 
2. Berry et al. 
(2012).  
USA 794 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
3. Chien et al. 
(2014) 
Taiwan 40 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Mean scores of decisional regret 
at T1 and T2 were low and did 
not change over time (β = 0·6, p > 
0·05).  
4. Christie et 
al. (2017) 
Australia 40 Male Prostate 
cancer 
Radical prostatectomy The single DRS item 
‘The choice did me a 
lot of harm’ 
Quantitative 
descriptive 
Not provided 
5.  Clark et al. 
(1997)  
USA 201 Male Prostate 
cancer 
Medical or surgical 
castration 
Three items tapping 
misgivings about the 
choice that was made 
and a wish to reverse 
that decision 
Mixed 
methods 
Not provided 
6. Collingwood 
et al. (2014) 
USA 556 Male Prostate 
cancer 
Robotic-assisted 
laparoscopic 
prostatectomy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
7. Cuypers et 
al. (2019) 
The 
Netherla
nds 
382 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
After 12 months, 15% of 
participants regretted their 
treatment choice. 
8. Davison et 
al. (2007)  
Canada 130 Male  Prostate 
cancer 
Radical prostatectomy, 
30% of sample 
received neoadjuvant 
hormone therapy also 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Men had no regrets over their 
decision to have surgery 
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Study 
no. 
Reference Country N  Gender Cancer  Treatment Type Measure of regret Study design Prevalence of regret 
9.  Diefenbach 
& Mohamed 
(2007)  
USA 793 Male Prostate 
cancer 
3-dimensional 
conformal radiation 
therapy, 
brachytherapy, 
prostatectomy 
Two items from the 
Decision Regret Scale 
Quantitative 
descriptive 
Not provided 
10. Fernandes‐
Taylor & 
Bloom 
(2011)  
USA 449 Female Breast 
cancer 
Not mentioned 'Looking back, is there 
anything about your 
treatment that you 
would do differently?' 
Mixed 
methods 
43% of women regretted their 
breast cancer treatment. 
11.  Goepfert et 
al. (2017) 
USA 172
9 
Male 
and 
female 
Orophary
ngeal 
carcinom
a 
Not mentioned  The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
38.6% of patients reported no 
regret (ie, proportional regret 
score of zero), 45.8% of patient 
had “mild” regret, and 15.5% of 
patients reported “moderate to 
strong” regret. 
12.  Hoffman et 
al. (2017) 
USA 934 Male Prostate 
cancer 
Not mentioned 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
Overall, 14.6% expressed 
treatment decision regret. 
13.  Holmes et 
al. (2017) 
USA 804 Male Prostate 
cancer 
Not mentioned 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
Overall, 13% of participants 
reported regret concerning their 
treatment decision. 
14.  Hu et al. 
(2008) 
USA 195 Male Prostate 
cancer 
Not mentioned 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
18% were regretful of their 
treatment choice. 
15.  Hurwitz et 
al. (2017) 
USA 652 Male  Prostate 
cancer 
Radical prostatectomy, 
external beam 
radiation therapy, 
brachytherapy, or 
active surveillance 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
At 36 months, 13%, 18%, 9%, and 
7% of patients reported low 
regret, and 5%, 7%, 0%, and 2% 
of patients reported high regret 
in the RP, EBRT, BR, and AS 
groups respectively. 
16.  Karuturi et 
al. (2019) 
USA 480 Female Breast 
cancer 
Endocrine therapy and 
chemotherapy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
The decision-regret score was 
17.2 for endocrine therapy and 
17.7 for chemotherapy. 
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Study 
no. 
Reference Country N  Gender Cancer  Treatment Type Measure of regret Study design Prevalence of regret 
17.  Kinsella et 
al. (2012) 
England 82 Male Prostate 
cancer 
Radical prostatectomy 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
randomized 
controlled 
trials 
Not provided 
18.  Lantz et al. 
(2005) 
USA 163
3 
Female Breast 
cancer 
Not mentioned “If I had it to do over, I 
would make a different 
decision about what 
type of surgery to 
have” 
Quantitative 
descriptive 
Not provided 
19.  Ratcliff et al. 
(2013) 
USA 95 Male Prostate 
cancer 
Radical prostatectomy Participants responded 
to seven items related 
to the frequency with 
which they had 
thoughts about how 
their current situation 
could have turned out 
more positively had 
they made a different 
treatment decision 
 
Quantitative 
randomized 
controlled 
trials 
Not provided 
20. Schroeck et 
al. (2008) 
USA 400 Male  Prostate 
cancer 
Retropubic radical 
prostatectomy or 
robot-assisted 
laparoscopic radical 
prostatectomy 
Regret was measured 
by a previously 
validated five-level 
Likert scale addressing 
whether patients 
wished they could 
have changed the kind 
of treatment they 
received. 
 
 
 
 
Quantitative 
descriptive 
19% of men reported regret. 
32 
Study 
no. 
Reference Country N  Gender Cancer  Treatment Type Measure of regret Study design Prevalence of regret 
21. Shakespeare 
et al. (2017) 
Australia 82 Male Prostate 
cancer 
Surgery and post‐
prostatectomy 
radiotherapy 
2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
16.9% were regretful of their 
overall treatment experience. 
22. Taha et al. 
(2011) 
Canada 260 Female Breast 
cancer 
Not mentioned Women with a breast 
cancer experience 
were asked to indicate 
on a 5-point scale 
ranging from 1 
(strongly disagree) to 5 
(strongly agree) how 
much she concurred 
with five statements 
regarding regret 
pertaining to her 
breast cancer 
treatment decisions 
(i.e., “I regret the 
choice that was 
made”) 
Quantitative 
descriptive 
Not provided 
23. van Tol‐
Geerdink et 
al. (2016) 
The 
Netherla
nds 
240 Male Prostate 
cancer 
Not mentioned 18 regret statements 
were developed, in 
part derived from 
previous studies. 
Quantitative 
randomized 
controlled 
trials 
Not provided 
24. Wang et al. 
(2018) 
Taiwan 154 Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
The mean score on the DRS for 
the study sample was 8.10. 
Overall, the sample reported low 
rates of decisional regret. 
25. Windon et 
al. (2019) 
USA 150 Male 
and 
Female 
Head 
and neck 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
 
 
 
 
Quantitative 
descriptive 
Participants expressed low levels 
of regret (median score, 5; IQR, 0‐
25 on a scale of 100). 
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26. Lin (2011) Taiwan 100 Male Prostate 
cancer 
Radical prostatectomy The original regret 
scale was developed by 
Clark et al and includes 
3 items: the patient's 
wish that he could 
change his mind about 
the type of treatment 
he received, his belief 
that his QOL would be 
better if he had chosen 
a different treatment 
option, and whether 
he was bothered by 
the fact that other men 
had received very 
different prostate 
cancer treatments. In 
this study, we added 1 
item to this scale: 
whether the man 
regretted that he had 
received an RP. 
Quantitative 
descriptive 
31% of the participants reported 
experiencing regret. 
27. Maguire et 
al. (2017) 
Ireland 
and 
Northern 
Ireland 
122
9 
Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
The mean Decisional Regret score 
of 18.02 suggests that levels of 
regret amongst were reasonably 
low, yet there was considerable 
variation here (SD = 19.52). 14.5% 
of survivors experienced high 
levels of regret (a score above 
50). 
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28. Mahal et al. 
(2015) 
USA 484 Male Prostate 
cancer 
Surgery or radiation 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
Not provided 
29. Martinez et 
al. (2013) 
USA 153
6 
Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale – altered 
for the purpose of this 
study to reflect 
elements specific to 
breast cancer surgery 
Quantitative 
descriptive 
Mean regret in the overall sample 
was 4.9 at time 1 and 5.4 at time 
2. 
30. Mollica et al. 
(2017) 
USA 109
3 
Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
31. Morris et al. 
(2015) 
USA 794 Male Prostate 
cancer 
Not mentioned 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
12% experienced treatment 
decisional regret. 
32.  Nicolai et al. 
(2016) 
Germany 160 Male 
and 
female 
Breast or 
colon 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
33. Calderon et 
al. (2019)  
Spain 403 Male 
and 
female 
Not 
specified 
Chemotherapy or 
radiotherapy or both 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
The mean DRS score was 10.6. 
Most participants (51.9%, n = 
209) experienced no decision 
regret. 
34. Chambers et 
al. (2018) 
Australia 28 Male Prostate 
cancer 
Not mentioned No specific measure of 
regret. However, men 
in the study mentioned 
feeling regret in the 
interview. 
Qualitative Not provided 
35. Davison et 
al. (2014) 
Canada 151 Male Prostate 
cancer 
Robotic-assisted 
laparoscopic radical 
prostatectomy or open 
radical prostatectomy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
The mean total decision regret 
score of patients in the RARP was 
19.34 (SD = 20) and the ORP 
group 21.32 (SD = 24.6). 
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36. Hacking et 
al. (2013) 
Scotland 123 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
37. Hawley et al. 
(2008) 
USA 203
0 
Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
About 39% had a lot of decision 
regret, 30% a moderate amount 
of regret and another 31% 
reported very little regret. 
38. Lee et al. 
(2015) 
USA 123 Female Breast 
cancer 
Mastectomy alone 
(50.4%) 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Women reported a low to 
moderate level of regret with 
their decision (M = 29.1, SD = 
19.0). 
39. Lam et al. 
(2013) 
China 276 Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trails 
Not provided 
40. Lam et al. 
(2014) 
China 286 Female Breast 
cancer 
Surgery The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
41. Sawka et al. 
(2012) 
Canada 44 Male 
and 
female 
Thyroid 
cancer 
Adjuvant radioactive 
iodine treatment 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Decision regret was generally low 
(mean 22.1, standard deviation 
[SD] 13.0). 
42. Schuermeye
r et al.  
(2016) 
USA 96 Male 
and 
female 
Uveal 
melanom
a 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
At the baseline, 10% (n=10) of 
patients had some or full decision 
regret. At 3 months, 17% (n=11) 
had some or full decision regret, 
while at 12 months, 10% (n=8) 
had some or full decision regret. 
43. Sepucha et 
al. (2015) 
USA 97 Male 
and 
female 
Breast 
cancer 
Surgery One item assessed 
whether patients 
would choose the 
same type of surgery 
again. 
 
Quantitative 
descriptive 
A little more than half of 
respondents (60.8%) would 
definitely have the same type of 
surgery again, indicating no 
regret. 
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44. Shepherd et 
al. (2019) 
Scotland 137 Male 
and 
female 
Colorect
al cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
45. Shuman et 
al. (2017) 
USA 57 Male 
and 
female 
Laryngea
l cancer 
46% treated surgically, 
54% nonsurgically 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
46. Spittler 
(2012) 
USA 102 Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Mixed 
methods 
The majority of the women 
reported low decision regret 
(79%) and of these 44% had no 
decision regret. 
47. Wagland et 
al. (2019) 
England 97 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Mixed 
methods 
Not provided 
48. Watts et al. 
(2014) 
Australia 138  Male  Prostate 
cancer 
Prostate specific 
antigen (PSA) testing 
(might need to exclude 
as not cancer 
treatment) 
The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
49. Mishel et al. 
(2009) 
USA 256 Male Prostate 
cancer 
Not mentioned Decisional Regret 
Subscale, a 3-item 
subscale of the Quality 
of Life Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
50. Step et al. 
(2009) 
USA 216 Female Breast 
cancer 
Adjuvant therapy Decision regret likert 
scale  
Quantitative 
descriptive 
Not provided 
51. Step et al. 
(2009) 
USA 179 Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
52. Parker et al. 
(2018) 
USA 288 Female Breast 
cancer 
Contralateral 
prophylactic 
mastectomy (CPM) 
 
 
 
The 5-item Decisional 
Regret Scale 
 
 
 
 
 
Quantitative 
descriptive 
Not provided 
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53. Repetto et 
al. (2016) 
Italy 204 Male Prostate 
cancer 
Active surveillance 
(AS), open radical 
prostatectomy, robotic 
radical prostatectomy, 
and brachytherapy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Most of the patients had a low or 
null degree of regret on the 
Treatment Regret Scale from 0 to 
100 (78.1% obtained a score <30, 
and about 30% of the sample had 
a score equal to zero). Only 4.7% 
scored 60 or more, indicating 
some degree of regret. 
54. Shahrzad & 
Seyedeh 
Narjes 
(2019) 
Iran 60 Female Breast 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
55. van Stam et 
al. (2018) 
The 
Netherla
nd 
454 Male Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
56. Noyan et al. 
(2006) 
Turkey 125 Female Breast 
cancer 
Mastectomy (and 
breast reconstruction) 
Satisfaction/regret 
likert scale 
Quantitative 
descriptive 
Not provided 
57.  Advani et al. 
(2019) 
USA 421 Female Breast 
cancer 
Lumpectomy plus 
whole-breast 
irradiation, 
brachytherapy, or 
endocrine therapy or 
mastectomy with or 
without radiation 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
23.8% of respondents reported 
experiencing local therapy 
decisional regret 
58. Hu et al. 
(2003) 
USA 96 Male Prostate 
cancer 
Not mentioned 2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
16% of participants reported 
regret. 
59. Steer et al. 
(2013) 
Australia 220 Male Prostate 
cancer 
Image-guided intensity 
modulated radiation 
therapy and 3-
dimensional conformal 
radiation therapy. 
 
2-item regret 
questionnaire by Clark 
et al. 
Quantitative 
descriptive 
3.8% of patients expressed 
decision regret for their choice of 
treatment. 
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60. Lavery et al. 
(2012) 
USA 703 Male Prostate 
cancer 
Robot-assisted 
laparoscopic 
prostatectomy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Of the patients 88% did not 
regret the decision to undergo 
robot-assisted laparoscopic 
prostatectomy. 
61.  Clark et al. 
(2003) 
USA 747 Male 
 
Prostate 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
62. Clark et al. 
(2001) 
USA 201 Male Prostate 
cancer 
Orchiectomy (29%) or 
chemical castration 
(71%) 
Two items asking if a 
patient wished he 
could change his mind 
and the belief that he 
would have been 
better off with the 
treatment not chosen. 
Quantitative 
descriptive 
23% of participants reported 
regret. 
63.  Drevdahl & 
Dorcy (2012) 
USA 45 Male 
and 
female 
Hematol
ogic 
malignan
cies 
Stem cell transplant Interview questions 
about regret 
Qualitative Noting that they had “no other 
choice,” participants expressed 
no regret posttransplant. 
64. Shaverdian 
et al. (2017)  
USA 276 Male Prostate 
cancer 
Stereotactic body 
radiation therapy, 
intensity modulated 
radiation therapy, or 
high-dose-rate 
brachytherapy. 
“A validated tool” Quantitative 
descriptive 
13% expressed regret with their 
treatment. 
65. Daum et al. 
(2017) 
USA 201 Male Prostate 
cancer 
Not mentioned The satisfaction with 
decision scale (Holmes-
Rovner et al., 1996) 
Quantitative 
descriptive 
Not provided 
66. Davison, B. 
J., & 
Goldenberg, 
S. L. (2003) 
Canada 67 Male Prostate 
cancer 
Radical prostatectomy 
External beam 
radiation, 
Brachytherapy, 
Watchful waiting. 
 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
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67. Diefenbach 
et al. (2008) 
USA 391 Male Prostate 
cancer 
External beam 
radiation 
Three items from the 
5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
68. Doğan et al. 
(2017) 
Turkey 162 Male Prostate 
cancer 
Not mentioned Interview question: Do 
you regret having 
undergone this 
surgery? 
Qualitative 16% regretted having undergone 
surgery, while another 1.7% had 
indecisive thoughts on regret. 
69. Mohamedali 
et al. (2010) 
Canada 35 Male 
and 
female 
Acute 
myeloid 
leukaemi
a 
Chemotherapy The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Decisional regret scores were low 
among respondents, with a mean 
score of 8.67 out of 25. 
70.  Reamer et 
al. (2017) 
USA 160 Male Prostate 
cancer 
Surgery, radiation, 
active surveillance 
(AS)/watchful waiting 
(WW). 
“Existing scales 
modified for study” 
Quantitative 
descriptive 
Men in the sample had little 
regret (median score: 1.0 on a 5-
point scale, SD: 0.8) with their 
treatment decision-making 
process. 
71. Sawka et al. 
(2015) 
Canada 70 Male 
and 
female 
Thyroid 
cancer 
Not mentioned The 5-item Decisional 
Regret Scale 
Quantitative 
randomized 
controlled 
trials 
Not provided 
72. Swanick et 
al. (2018) 
Canada 165
0 
Female Breast 
cancer 
Lumpectomy plus 
whole-breast 
irradiation, 
lumpectomy plus 
brachytherapy, 
lumpectomy alone, 
mastectomy without 
radiation therapy, and 
mastectomy plus 
radiation therapy 
The 5-item Decisional 
Regret Scale 
Quantitative 
descriptive 
Not provided 
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2.5.2 Narrative Synthesis  
The assessment of each full-text revealed different types of factors associated with the 
emergence of regret in cancer patients/survivors. These factors were noted and later split into 
categories, according to their nature, e.g., a study which found ethnicity to have an 
association with regret was put into the ‘socio-demographic factors’ category. Most studies 
examined factors which fit into more than one category. Those categories were then further 
grouped into two broad sections: “less modifiable factors” and “modifiable factors” 
associated with regret (see Table 3).  During the analysis, a clear distinction between the two 
was noted. Specifically, modifiable factors were considered to be those that may be changed 
from the patient’s perspective, e.g., a patient feeling distressed post-treatment may reach for 
professional help in order to mitigate this feeling. There are also factors which the patient has 
no control over, e.g., socio-demographic factors like age. Less modifiable factors were those 
which the patient had little or no control over. 
Table 3 
The categories of factors found to be associated with regret  
  
Less modifiable factors associated with 
regret 
Modifiable factors associated with regret 
Socio-demographic factors Decision making process, the consultation, 
level of understanding of information 
received or searched for/ counselling, etc. 
Clinical factors, health status and physical 
side effects 
Psychological and social factors 
Treatment type  
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2.5.3 Theme 1: Less modifiable factors associated with regret 
In the analysis of less modifiable factors, the factors were further organised into three 
categories: socio-demographic factors, clinical factors (or factors associated with the patient’s 
health status including side effects experienced) and factors associated with the treatment 
type received. It is important to note that while some patients in the studies did have control 
over the treatment chosen, the nature of the treatment itself was considered a less modifiable 
factor here as the patient has no control over the effects of treatment. In contrast, treatment 
decision-making was considered as a modifiable factor in a category in Theme 2. 
1. Regret associated with socio-demographics  
Twenty-two (31%) of the studies (2, 3, 6, 8, 9, 12, 14-16, 18, 20, 28-31, 37, 50, 51, 
56-58, 60) in the analysis reported an association between regret in cancer patients/survivors 
and specific socio-demographic factors including: marital status (2, 14; regretful men were 
less likely to be in a relationship), education level (2, 3, 16, 18, 30, 50, 51, 56, 57, 58; higher 
education associated with less regret), race (6, 14, 15, 16, 18, 20, 28, 29, 30, 31, 37, 57; 
Caucasian patients in the USA tended to regret less than other racial groups), age (9, 12, 16, 
31, 50, 51, 60; no clear pattern found, both younger and older patients were found to 
experience regret in different studies), income level (18, 56; higher income associated with 
less regret) and post-treatment financial difficulties (8; financial difficulties associated with 
higher regret). 
Some interesting patterns may be observed here. All of the studies concerned with 
race in cancer patients found that Caucasian individuals often reported less regret than non-
white patients. This was true for both males and females. However, it is important to note that 
all of those studies were conducted in the USA, where racial differences may be more 
apparent. Another pattern which appeared from the analysis of socio-demographic factors in 
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the studies suggests that lower education levels may be associated with the emergence of 
regret in cancer patients/survivors. This was also found to be the case with lower-income 
levels. No clear pattern was found in the levels of regret in different age groups as various 
studies found more regret in younger and older patients. None of the studies analysed 
reported a comparison of the emergence of decisional regret between males and females. This 
is likely due to the focus on recruitment of patients with specific cancer types, which 
differentially affects males and females. The studies which conducted an analysis of socio-
demographic factors and their relationship with regret can be found in Table 4 below. 
2. Regret associated with clinical factors, health status and physical side effects 
Twenty-four (33%) of the studies (6, 8-12, 14, 15, 17, 19, 20, 24, 26, 29, 30, 31, 35, 
45, 58, 60-64) found an association between the patient’s health status pre and/or post-
treatment and the emergence of regret. This also included the experience of side effects from 
cancer or treatment.   
Prostate cancer patients were the largest group of participants in this review. 
Therefore, the largest number of physical factors associated with regret were prostate cancer 
specific. Prostate cancer patients reported regret associated with: poorer physical health (14), 
lower health related quality of life (HRQoL) scores (35, 58, 60), lower scores on the 
functional and global QoL subscales (33, 67), poorer physical component summary scores 
(14), surgical complications (6), sexual dysfunction/ urinary dysfunction/ erectile dysfunction 
(6, 9, 12, 15, 17, 19, 26, 31, 35, 60, 61), pain (8), bowel function bother (12, 14, 26), poor 
hormonal function (15), nausea (62), lower Expanded Prostate Cancer Index scores (20), 
poorer perceived physical condition (26), higher Gleason score (30, 64), PSA level/concern 
(12, 61, 64) and T1c disease (64). In contrast, one study found that regretful men less 
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frequently reported sexual dysfunction (62). Interestingly, one study found that non-obesity 
in African men was associated with greater regret levels (6).  
Breast cancer patients similarly reported regret associated with a range of physical 
health problems. These included: premature menopause (10), later breast cancer stage (24) 
and a second diagnosis of breast cancer (29). Difficulty swallowing was a factor associated 
with regret in oropharyngeal carcinoma patients (11). Laryngeal cancer patients reported 
regret associated with lower voice-related QoL (45). A study of patients with hematologic 
malignancies (63) found that regret was associated with the patient’s perceived decreased 
cognitive abilities. While all of the studies reported different health-related factors, it is clear 
that poorer physical health may be associated with the emergence of decisional regret. 
Studies which analysed the relationship between clinical factors, health status, physical side 
effects and regret can be found in Table 4 below. 
3. Regret associated with the treatment type received 
Treatment type chosen/received was found to be associated with regret in twenty-six 
(36%) of the studies in this analysis (6, 9-11, 14, 17, 18, 20, 21, 24-26, 29, 31, 41, 52, 56-59, 
60, 62, 64, 66, 69, 72,). The studies in this analysis included various cancer patients who 
underwent different treatments; therefore, no pattern of regret associated with specific 
treatment types was found. Some of the studies did not report on the specific type of 
treatment, while others provided this information in detail. Some of the treatments found to 
be associated with higher regret in prostate cancer individuals in the studies were: medical or 
surgical castration, robotic-assisted laparoscopic prostatectomy, brachytherapy, androgen-
deprivation therapy and radical prostatectomy.  
Breast cancer patients regretted radiation, chemotherapy, hormone therapy, surgery, 
mastectomy, lumpectomy, axillary nodal dissection and others. Oropharyngeal carcinoma 
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patients regretted therapeutic combination treatment. Head and neck cancer patients regretted 
undergoing surgery or radiation therapy alone instead of a combination of treatments (25). 
One study (9) found an association between regret and treatment modality. One study (18) 
found regret in breast cancer patients who decided to not undergo breast reconstruction post-
mastectomy. Three studies (14, 60, 69) found that a longer interval since treatment in cancer 
patients was associated with greater regret, while another (6) found that longer stay in 
hospital post-treatment resulted in higher reports of regret. The same study (6) found that 
African American men who received secondary therapy reported more decisional regret than 
white men, suggesting not only an association between regret and treatment type but also 
ethnicity. This shows just how difficult it may be to predict and to mitigate the emergence of 
regret, as more than one factor may be involved.  
2.5.4 Theme 2: Modifiable factors associated with regret 
Modifiable factors are those which either the doctor or patient may clearly have some 
control over. In the analysis, these factors were further split into two broad categories: regret 
associated with the decision-making process and regret associated with social/psychological 
factors.  
1. Regret associated with the decision making process (e.g., consultation/level of 
understanding of information received or searched for/ counselling) 
This category of the analysis was the one most commonly investigated in the studies 
reviewed. It included all factors associated with the decision making process, the consultation 
with health specialists, the level of understanding of the information provided by doctors or 
searched for by the patient. Thirty (42%) of the studies analysed (1, 2, 7, 10, 12, 13, 17, 18, 
23, 24, 26, 30-32, 34, 36, 38-41, 43, 44, 46-49, 51, 55, 62, 68) explored the associations 
between these factors and the emergence of decisional regret in patients.  
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The patients in the studies analysed reported regret associated with the decision 
making process for many reasons. A number of studies (1, 2, 68) found that regretful patients 
believed to have received incomplete information regarding their diagnosis or treatment, or 
that their perceived preparation for decision-making was low. Decision uncertainty and 
decision conflict was found to be associated with regret in four studies (30, 38, 40, 46), while 
confidence level was found to be negatively correlated with decision regret in another (46). 
One of those studies (38) also found an inverse significant relationship between the level of 
comfort in using the English language and difficulty with communication with physicians and 
decisional regret. One study (43) found lower decision regret in patients who received 
treatment which matched their goal, suggesting the importance of goal setting prior to 
treatment decision making. 
Four studies found that decisional regret was negatively associated with satisfaction 
understanding potential treatment side effects (10, 31, 47, 68). Another study (47) also found 
this to be the case and found that unchallenged treatment preferences and an absence of 
clinical recommendations resulted in higher levels of regret. One study (40) found regret to 
be significantly predicted by lower quality in establishing a shared decision-making 
framework, being offered multiple treatment options and greater duration of consultation. 
One qualitative study (10) notes that women regretted having chemotherapy for breast cancer 
as they were not aware that this may decrease their chance of having children in the future. 
The same study also found that many women expressed regret associated directly with the 
doctor in charge of their treatment, one noting that her doctor did not have enough time for 
her and another one stating that her doctor had no “bed-side manner”. Several women in this 
study also regretted not being more active in seeking information about their treatment and 
not knowing enough about its possible side effects. One study (34) reports of patients who 
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described feeling regret about late diagnosis or treatment and this was commonly attributed to 
delays by clinicians.  
Six studies (23, 36, 39, 44, 48, 49) found less regret in patients who were given a 
decision aid, than in those who were not. In contrast, one study (7) found that the receipt of a 
decision aid had no statistically significant association with lower odds of reporting regret. In 
another study (41), decision regret significantly differed according to who made the final 
decision: the patient (mean 19.0, SD 11.3), patient and doctor (mean 19.5, SD 7.4), and the 
doctor (mean 32.9, SD 20.37). Another study (17) found that preoperative counselling altered 
treatment choices in prostate cancer patients and those who received this counselling 
experienced far less treatment-related regret than those in the control group. Finally, one 
study (32) found more regret in patients who reported not feeling empathy from their 
physician. 
  Two patterns have been found in the studies analysed above. The first being that a 
number of studies (12, 13, 26, 62) found less regret in patients who reported being well-
informed at the time of the treatment decision. The second being that less regret was found in 
patients who had as much involvement in the decision-making process as desired, i.e., 
patients who were not more involved than preferred, or less involved than preferred reported 
less regret across a number of the studies (18, 24, 32, 47, 51, 55, 68). 
2. Regret associated with psychological and social factors 
Twenty-one (29%) studies (2-5, 7, 8, 10, 14, 15, 19, 22, 26, 27, 30, 33, 37, 40, 42, 63, 
67, 68) in the analysis found an association between psychological or social factors and the 
decisional regret in cancer patients. A pattern suggesting that regret is associated with poorer 
mental health is evident in all of these studies, with two (15, 19) simply reporting an 
association between regret and poorer mental health scores. Four studies found regret to be 
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associated with higher anxiety scores (2, 7, 40, 42), with another two (14, 27) finding an 
association between regret and fear of recurrence. Three studies found regret to be associated 
with higher depression scores (4, 7, 42). Two studies (5, 33) found that the more distress 
displayed by patients, the higher the levels of decisional regret, with an additional study (26) 
reporting more regret in patients displaying distress from treatment complications. One study 
(14) found that emotional domains differed between regretful and non-regretful people. This 
result was mirrored by another study (3) which found that patients with greater psychosocial 
adjustment experienced less regret. Another study (30) found that patients who displayed 
higher optimism and resilience also reported less regret. Another study (63) reports higher 
levels or regret to be associated with feelings of wanting to return to “normal”. Another study 
(22) found regret to be associated with blaming oneself for negative events associated with 
the illness.  
Three studies (10, 37, 68) found an association between social support and decisional 
regret, with more support being associated with less regret. Perceived poorer self-care habits, 
for example in the form of not joining a support group, were also associated with higher 
levels of regret (10). One study (8) found a correlation between higher levels of regret and 
changes in QoL in men with decreases in role and social functioning. Lastly, two studies (14, 
30) found higher levels of spirituality to be associated with lower levels of regret. 
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Table 4 Studies which investigated the relationships between regret and five types of factors 
Category Factor Studies with sig. relationship Studies with no sig. 
relationship 
Studies with partial 
relationship 
 
Socio-
demographic 
variables 
Marital status 2, 14   
Education level 2, 3, 16, 18, 50, 51, 56, 57, 58 30, 37, 68  
Socioeconomic status  6  
Race/Ethnicity 6, 14, 15, 16, 18, 28, 29, 30, 31, 
37, 57 
20  
Age 9, 12, 16, 31, 50, 51, 60   
Employment status 9   
Income level/ financial difficulties 8, 18, 56   
 
Clinical factors, 
health status and 
physical side 
effects 
General physical health condition/ HRQoL scores/ 
QoL scores 
14, 26, 33, 35, 58, 60, 67 53  
Non-obesity 6   
Cancer stage 24, 64 20  
Gleason score 30, 64 20  
Biochemical recurrence  20  
Lower EPIC domain scores 20   
Health utility  57  
Sexual dysfunction/erectile dysfunction 6, 9, 12, 15, 17, 19, 26, 35, 60, 61 62, 68  
PSA level/ PSA concern 12, 61, 64   
Urinary dysfunction 9, 19, 26, 31  15, 35 
Pain 8   
Bowel dysfunction 12, 14, 26   
Hormonal dysfunction 15   
Nausea  62   
Premature menopause 10   
Second diagnosis of cancer 29   
Difficulty swallowing 11   
Voice-related quality of life 45   
Perceived decreased cognitive abilities 63   
 
Treatment factors 
Surgical complications 6   
Prostate cancer treatment  6, 9, 17, 20, 21, 26, 31, 58, 59, 62, 
64 
66  
Breast cancer treatment 10, 11, 19, 24, 29, 56 52, 72 57 
Head and neck cancer treatment 25   
Thyroid cancer treatment  41  
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Longer interval since treatment 14, 60, 69   
Longer stay in hospital post-treatment 6   
Treatment modality 9   
 
Decision making 
process 
Being well-informed  1, 2, 10, 12, 13, 26, 62, 68   
Decision uncertainty 38   
Confidence level 46   
Communication difficulty 38   
Matched goal 43   
Understanding potential side effects 10, 31, 47, 68   
Decisional conflict  30, 40, 46   
Little SDM 40, 41   
Being offered multiple treatment options 40   
Greater duration of consultation 40   
Blaming health-care professionals 10, 32, 34   
Use of decision aid 23, 36, 39, 44, 48, 49 7, 54, 71  
Preoperative counselling  17   
Preferred level of involvement 18, 24, 32, 47, 51, 55, 68   
Unchallenged treatment preferences 47   
Lack of clinical recommendations 47   
 
Psychological and 
social factors 
Overall poor mental health scores 15, 19   
Anxiety 2, 7, 40, 42   
Depression 7, 42  4 
Distress 5, 26, 33   
Emotional domains of QoL 3, 14, 30   
Wanting to return to “normal” 63   
Fear of cancer recurrence 14, 27   
Blaming oneself for negative events 22   
Social support 10, 37, 68 70  
Poor self-care habits 10   
Changes in QoL with decreases in role and social 
functioning 
8   
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2.6 Discussion 
The aim of this review was to understand the complexity of factors which may have 
an impact on the emergence of decisional regret in cancer patients. Results show that the 
level of regret found in patients in the studies analysed was quite low, which mirrors findings 
from previous systematic reviews (Hoffman et al., 2017; Spittler, 2012; Steer et al., 2013). A 
systematic review of 90 studies investigating whether regret in cancer patients is 
longitudinally-stable found that less than 20% of patients experienced any regret (Aarhus & 
Huang, 2020). However, the current review found that regret was often found in a significant 
minority of patient samples. The decrease in well-being in the presence of regret suggests that 
minimising the risk of this is an important consideration in supporting survivors achieve a 
better and healthier cancer survivorship.  
Two broad types of factors emerged from the analysis – less modifiable factors 
associated with regret and modifiable factors associated with regret. The first are factors 
which a cancer patient/survivor has little or no control over. They may relate to life pre-
diagnosis or be directly related to the illness and the experiences it brings. The second are 
factors which may be altered or controlled by the patient or their doctor. For some patients 
experiencing regret, it may be too late to alter some factors discussed below in order to 
mitigate their regret. For example, a patient reporting regret cannot go back in time to change 
the treatment decision-making process. However, this research may help inform the provision 
of supports for cancer survivors. It is hoped that the results of this analysis can be used in 
order to inform future interventions aimed at those concerned, thereby mitigating the 
emergence of regret in cancer patients and survivors. While many of the factors in this 
category are “fixed”, i.e., cannot be changed, these findings may be of use to clinicians who 
wish to identify patients prone to experiencing regret.  
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2.6.1 The role of sociodemographic and health-related factors in the experience 
of regret 
The patterns found amongst socio-demographic factors linked to the emergence of 
regret show that less regret occurs in those who are: in a relationship, have a higher education 
and have a higher income (or less financial difficulty caused by cancer/treatment). In all of 
the studies concerned with ethnicity, white individuals were found to report less regret than 
non-white cancer patients/survivors (Collingwood et al., 2014; Kim et al., 2016). It is 
important to note however that all of those studies were conducted in the USA which limits 
the generalisability of results. No differences or patterns found in age, with various studies 
finding younger patients to report more regret, and older patients in others. It is also notable 
that no studies in the review performed an analysis of gender differences in decisional regret 
of cancer patients. However, most studies included focused on breast or prostate cancer only 
and therefore would not have been able to conduct this analysis. This is something which 
should receive more attention in the future in order to establish whether cancer supports 
should be tailored differently to men or women. While such socio-demographic factors 
cannot be altered, this review highlights various groups of patients which need to be looked 
out for during their illness, as they may be increasingly prone to experiencing decisional 
regret. 
The results also indicate that overall poorer physical health and the experience of 
negative side effects is associated with greater levels of decisional regret in cancer patients 
(Berry, Wang, Halpenny, & Hong, 2012; van Stam et al., 2018). While one surprising study 
result suggests that non-obesity in African-American men can be associated with higher 
regret levels (Collingwood et al., 2014), overall, this analysis found a relationship between 
poorer health status and higher levels of regret. While in most cases, poorer physical health 
cannot be avoided, it may be possible to prepare patients for what is to come after cancer 
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treatment. The finding that many patients reporting regret also report negative physical side 
effects suggests that providing information about what is to come after treatment is vital. The 
longevity of these symptoms also needs appropriate consideration, as it is important to 
understand that physical side effects can continue long into survivorship. This may be done 
with appropriate decision aids which have been found to improve satisfaction post-treatment 
(Kearing, Berg, & Lurie, 2016; Whelan et al. 2014). The review also highlights that patients 
tend to regret side-effects which they were not aware of while making their treatment 
decision, leaving them no time to prepare for the negative outcomes of their chosen treatment 
type. Healthcare professionals need to take this into account when preparing patients for the 
aftermath of the cancer treatment. 
2.6.2 The role of the cancer treatment in the experience of regret 
The review did not find any clear pattern between the emergence of decisional regret 
and specific treatment types. However, findings highlight the variety of cancer treatment 
types which may be associated with regret in cancer patients and survivors, suggesting that 
regardless of treatment, all survivors are at risk of experiencing regret (Fernandes-Taylor & 
Bloom, 2011; Lin et al., 2011; Ratcliff et al., 2013). This finding suggests the importance of 
choosing the “best” treatment option available for specific patients. Naturally, regret may 
occur despite the patient and/or doctor feeling like an appropriate treatment type was selected 
and this may occur for many reasons, including negative physical side effects experienced 
post-treatment, the treatment not working, or a long stay in hospital due to the treatment. 
Despite this, the review findings suggest that assisting cancer patients in their decision 
making may be of benefit. 
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2.6.3 The role of treatment decision-making in the experience of regret 
The review finds that overall, the better informed patients are before making their 
treatment decision, the less regret they report post-treatment (Lam et al., 2013; van Tol-
Geerdink et al., 2016). However, it is important to note that little regret is reported by cancer 
patients whose wishes regarding a desired level of involvement in the decision-making are 
met. This finding has also been found in a systematic review of cancer patient’s involvement 
preferences (Hubbard, Kidd, & Donaghy, 2008). It is important to understand that patient 
involvement preferences vary (Marahrens et al., 2017; Sekimoto et al., 2004). The review 
finds that the best regret-related results are found in those who are as much involved in the 
decision-making as they wish. Some patients do not feel the need to be involved in the 
decision-making process and prefer to leave the decision up to their doctors. Honouring this 
decision leads to less regret in patients (Nicolai et al., 2016). Future interventions should aim 
to assess involvement preferences for patients. This would allow healthcare providers to 
establish an appropriate method of decision-making.  
The review also found that doctors of cancer patients have an impact on the 
emergence of decisional regret. Individuals report more regret if they feel their doctors were 
not empathetic enough, had no bedside manner or were not understanding enough (Nicolai et 
al., 2016). Good communications skills, empathy and understanding are essential for the 
well-being of patients implying that more training could be provided to doctors in this area 
(Fallowfield, 2008; Kee, Khoo, Lim, & Koh, 2018). Effective doctor-patient communication 
is also essential for patient understanding (Janz et al., 2017), and as discussed above, this 
minimised the emergence of regret. These findings suggest that healthcare professionals 
should recognise the importance of appropriate care of not only the physical needs of the 
patient, but also the psychological needs. 
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Additionally, less regret was found in those who reported less decision uncertainty at 
the time of the treatment decision-making, those who felt like the treatment they selected 
matched their goal and those who used a decision aid. These findings suggest the importance 
of selecting an appropriate decision-making style, as this factor may strongly influence the 
emergence of decisional regret (Lam et al., 2014; Sawka et al., 2012; Wang et al., 2018). Not 
only is an appropriate decision-making style important as once again it is evident that well-
informed patients report better outcomes (Heisig et al., 2015; Manne et al., 2010). This 
pattern has been evident through different aspects of this analysis implying that cancer 
patients should not be treated as individuals who know far less than the health-care 
professionals. Honouring their input, feelings and knowledge is important for their well-
being.  
2.6.4 The role of psychosocial factors in the experience of regret 
The review found a relationship between higher levels of regret and poorer mental 
health scores (Chien et al., 2014; Hu et al., 2008; Wilson et al, 2017). This pattern is evident 
amongst all of the studies which measured the relationship between regret and psychological 
factors. Less regret was found in patients who displayed: less anxiety, less depression, less 
fear of cancer recurrence, and less distress. Some studies found that survivors with lower 
regret reported greater psychosocial adjustment, higher optimism, higher resilience, and 
higher spirituality. Other aspects of survivor appraisals emerged as associates of regret in 
some studies, including not blaming themselves for the negative events associated with their 
illness and not displaying a “need to go back to a normal life”. A cancer diagnosis brings a 
great psychological strain on its sufferers (Hewitt, & Rowland, 2002), and the link between 
poor mental health and high levels or regret is evident throughout this review. This finding 
highlights the need for doctors to be mindful of not only the physical well-being of their 
patients, but also the psychological impact that a cancer diagnosis and treatment may have on 
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them (Zebrack, 2011). Healthcare professionals should inform individuals of available 
interventions which aid psychological well-being in cancer patients, e.g., music interventions 
(Bradt, Dileo, Magill, & Teague, 2016; Zhang et al., 2012), yoga (Lin, Hu, Chang, Lin, & 
Tsauo, 2011), meaning-centred group psychotherapy (Breitbart et al., 2015), mindfulness 
stress reduction training (Bränström, Kvillemo, Brandberg, & Moskowitz, 2010) or other 
psychological interventions (Casellas-Grau, Font, & Vives, 2014; Jassim, Whitford, Hickey, 
& Carter, 2015). 
Social support (Mollica, Underwood, Homish, Homish, & Orom, 2017) was also 
found to be associated with less regret, although this factor was less frequently studied in the 
research review. While social support cannot be forced by the patient or healthcare 
professional, doctors should inform patients of the support services available on- and offline 
(Attai et al., 2015; Bender, Jimenez-Marroquin, & Jadad, 2011; van Uden Kraan et al., 2008). 
Spirituality also cannot be orchestrated. Once again, doctors may suggest religion-based 
support groups to cancer patients who may want it.  
Surprisingly, caregiver and family influence on decision making and related regret 
was not a factor identified in the studies reviewed. Family members are often involved 
before, during and after the medical consultation and may stimulate discussion at home, away 
from the medical expert (Laidsaar-Powell et al., 2016). They may also stimulate patient 
autonomy as they help to breakdown difficult to understand or overwhelming information 
(Laidsaar-Powell et al., 2016). However, as with personal involvement in decision-making, 
patients hold preferences on the level of involvement of their caregivers and family members 
(Laidsaar-Powell et al., 2016). An unsatisfactory level of involvement in decision-making as 
seen by the patient may affect the emergence of decisional-regret. 
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No consistent pattern of factors associated with regret was found between different 
cancer types, suggesting that any type of cancer warrants the possibility for regret to occur 
due to different factors. This also suggests that while systematic reviews concerned with the 
well-being of cancer patients of one cancer type only can allow researchers to better 
understand regret in a specific cohort, this also may restrict the generalisability of results 
(Lin, Aaronson, Knight, Carroll, & Dudley, 2009; Zhong, Smith, Haghighi, & Mancuso, 
2018). From this review it seems that regret in cancer patients can be treated as a general 
issue and not one that varies according to the type of illness. 
It is important to note that not all of the relationships found between regret and a 
specific factor were significant. Furthermore, a significant relationship between decisional 
regret and another factor cannot be interpreted as a cause of the emergence of regret. The 
inconsistent findings suggest the complexity of factors which may affect the emergence of 
decisional regret and that it may not always be easy to predict those who are at risk of regret. 
2.7 Limitations 
It is possible that the search terms relating to decisional regret used in the database 
search did not uncover all studies investigating regret, due to different phrasing used to 
describe this phenomenon. However, it was the intention to focus on this experience 
specifically, and the search term was in line with other systematic reviews in the area. 
Another limitation may be the number of databases used. The use of additional databases 
could have ensured the inclusion of more relevant studies. Another limitation of the current 
study is that any measure which attempted to capture the experience of regret was considered 
for inclusion and while most of the studies included used validated measures, some studies 
did not. Similarly, the reliability of the studies was not considered and neither was the 
statistical power of the studies in relation to the magnitude of variables associated with regret. 
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The type of studies included in the review may also be considered as a limitation of 
the current research. The majority of the studies included used a cross-sectional design 
making it difficult to make assumptions of causality. Very few of the studies were 
prospective, and this limited the results to one time point only. Studies which captured regret 
with various means (self-reported measures, qualitative measures, open-ended questions, 
close-ended questions) were included in the review. However, the search terms may not have 
picked up various measures with single items measuring regret, for example patient-reported 
outcomes. 
This review intended to be very inclusive and attempted to inspect the factors 
associated with decisional regret in patients suffering from various types of cancer, in 
comparison with other systematic reviews on the topic (Christie et al., 2015; Flitcroft et al., 
2018; Wilson et al., 2017). However, most of the studies which met the inclusion criteria 
were concerned with either prostate cancer patients only (58.33%) or breast cancer patients 
only (27.78%). This result mirrors the prevalence of prostate and breast cancers worldwide, 
with breast cancer being the second most common cancer worldwide (2.09 million cases) and 
prostate cancer being the fourth (1.28 million cases) (World Health Organisation, 2018). 
Lung and colorectal cancers are also very prevalent, but not as much research is being 
conducted about the regret in survivors of these cancer types. This may be because lung and 
colorectal cancers are top of the list of cancers which cause most deaths, and a smaller 
number of survivors than breast and prostate cancers (World Health Organisation, 2018). 
Nevertheless, this review highlights the need for researchers of well-being in cancer survivors 
to be more inclusive, as sufferers of less prevalent cancers are currently being overlooked. 
In some cases, it is unclear whether the physical side effects reported by the 
participants in the studies included occurred due to the cancer itself, or the treatment 
underwent. Therefore, this analysis undoubtedly contains side effects occurring for both 
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reasons, so should be interpreted with caution. Regret in cancer patients/survivors in these 
studies was associated with a wide range of factors. 
Lastly, USA is overly represented in the studies analysed. This may limit overall 
generalisability as healthcare contexts may differ in the USA compared to other countries. 
2.8 Conclusion 
It has been found that most systematic reviews of regret in cancer patients have 
concentrated on one cancer type only. This limits the generalisability of the results to other 
cancer populations. This review was conducted in order to create a broader overview of the 
reasons why survivors of different cancer types may report regret post-treatment. The results 
of the review present the complex nature of the many factors which may have an effect on the 
emergence of the negative feeling that is regret in cancer patients and cancer survivors. As 
regret can be an obstacle to full-recovery from cancer (Davidson et al., 2007), this review 
suggests that more research into mitigating its emergence is needed. The research available 
today highlights the complexity of factors associated with regret in cancer patients and 
survivors. However, more attention needs to be directed towards finding interventions of 
minimising it – interventions which will inform both the patient and doctor as well as 
interventions which will work to mitigate regret. 
In summary, this chapter has illustrated the range of factors found to be associated with the 
emergence of decisional regret in cancer patients and survivors. Study 2 aims to explore this 
further by examining the relationships between factors associated with the emergence of 
regret in cancer survivors living in Ireland. 
 
 
59 
Chapter 3 
Study 2 - An Analysis of the Factors Associated with Post-Treatment Regret in Cancer 
Survivors Living in Ireland - Method
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3.1 Overview 
The systematic review detailed in Chapter 2 uncovered the factors most commonly 
associated with regret, including sociodemographic variables, the treatment type undertaken, 
physical wellbeing and side effects, the decision making process, and psychosocial factors. 
Building on these findings, study 2 aimed to explore the experiences of cancer survivors 
living in Ireland. In this chapter, the methodology for this study is described in more detail. 
3.2 Aim of the Study 
The aim of this study was to explore the experiences of Irish cancer survivors in 
relation to their treatment decision-making, and to establish factors associated with decisional 
regret. More specifically, the study had three main objectives: 
1. To describe the characteristics of a sample of Irish cancer survivors who have 
undergone treatment. 
2. To understand the experiences of decision making in relation to cancer treatment. 
3. To explore the associations between sociodemographic, health, decision making, and 
psychosocial factors and the experience of decisional regret. 
3.3 Sample 
The sample comprised of cancer survivors living in Ireland. Inclusion criteria were 
being at least one-year post diagnosis, over 18 years of age, having undergone cancer 
treatment and currently not being a cancer patient. Participants who were cancer free but at 
the time of the study still undergoing treatment (e.g. medication) were included. A further 
inclusion criterion included being fluent English speaking. Participants were recruited from 
both online and community cancer support groups between January 2019 and September 
2019. More information on the recruitment process is provided in section 3.6. 
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3.4 Design 
 The study employed a cross-sectional survey design, with the main outcome variable 
being decisional regret. The study also used mixed methods to gain an in-depth insight into 
participant’s experience of their illness: from the time of diagnosis, through to treatment 
decision making and current survivorship. 
3.5 Measures 
A questionnaire was designed based on previous literature investigating the well-
being of cancer patients and/or cancer survivors, also informed by the findings of the 
systematic review. The survey included validated scales and sets of questions, most of which 
have featured in other studies concerned with the well-being of cancer patients and/or cancer 
survivors. Measures included were those hypothesised to associate with treatment decision 
making and in particular with the experience of decisional regret. Responses were obtained 
using Qualtrics, a web-based survey tool (Qualtrics, Provo, UT). All sections of the 
questionnaire underwent a thorough analysis which allowed for the inclusion of relevant 
questions only. The full questionnaire can be found in Appendix D. 
3.5.1 Sociodemographic and Health Information 
The first section of the survey obtained participants’ socio-demographic and 
background information as well as information regarding their health and cancer diagnosis. 
Participants were asked to report their: age, gender identity (male, female, other), nationality 
(Irish, other), number of dependent children, marital status (married, never married, 
widowed, separated, divorced, living with partner/co-habiting, living in a civil partnership), 
highest education level obtained (primary, secondary or third level), employment status 
(working for an employer, looking after family/home, unable to work due to permanent 
sickness/disability, self-employer, retired, student, unemployed, other), including whether 
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employment status had changed since diagnosis, and whether they had caring responsibilities 
for a family member (feeding, dressing, etc.). Participants were also asked about their ability 
to make ends meet. Specifically, participants were asked to rate their agreement with the 
question “Thinking of your total monthly income: are you able to make ends meet?” on a 
scale of 1 (very easily) to 7 (with great difficulty).  
Participants were asked a number of questions about their cancer diagnosis. This 
included reporting on their: time since diagnosis in years, cancer type diagnosed with (open 
text response), and whether they experienced any other chronic health conditions (open-text 
response).  
3.5.2 Cancer Treatment and Decision Making Process 
The second section of the survey was concerned with the treatment decision making 
process, the amount of treatment options which were available to respondents, how well 
informed the participants were of their treatment options, the type of information searching 
which the participants were involved in, as well as their subjective experience of the support 
provided by their health professional. The questions used in this section were adapted from 
The PiCTure Study (Prostate Cancer Treatment, your experience; Drummond et al., 2018) 
and The 9 Item Shared Decision Making Questionnaire (SDM-Q-9: Müller, Hahlweg, & 
Scholl, 2016).  
Respondents were asked to describe their primary treatment, to state how long ago 
they undertook the treatment and to note whether the treatment was currently ongoing in 
open-text style response boxes. They were also asked whether when making their decision, 
was there more than on treatment option available, was there anybody else they spoke to 
about their treatment options and whether they feel they had enough time to make the 
decision. Additionally, the participants were asked if they sought a second medical opinion 
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prior to making a treatment decision, if the possibility of side effects affected their decision, 
whether they sought information about treatments online (if yes, how much time they spent 
doing so, marked on a scale of 1 (very little time) to 7 (a lot of time)) and how well informed 
they felt at the time of the decision. In all cases, respondents indicated either “yes” or “no”. 
Lastly, the participants were asked to rank in terms of importance the three people who 
mostly influenced their decision regarding treatment from.  
The SDM-Q-9 (Simon et al., 2006), a valid and reliable tool (Kriston et al., 2010; 
Nejati ey al., 2019) requires participants to indicate their agreement with nine statements 
relating to their treatment decision-making process, e.g. “my doctor made clear that a 
decision needed to be made”, “my doctor wanted to know exactly how I wanted to be 
involved in making the decision”. More specifically, the questions related to the involvement 
the participant and their doctor had in the decision. Participants were asked to indicate their 
agreement with the statements on a scale of 1 (Completely Agree) to 6 (Completely 
Disagree). At least seven items must have been completed in order to extract a score from the 
SDM-Q-9. No score was computed if less than six items were completed, as it is not 
recommended to do so (Kriston et al., 2010). In order to convert the scores into a 0-100 scale, 
1 was subtracted from each item, the items were added and the sum was multiplied by 20/9. 
A score of 0 indicated high perceived SDM and a score of 100 indicated low perceived SDM. 
The SDM-Q-9 has good internal consistency (Calderon et al., 2018; Kriston et al., 2010; 
Rencz et al., 2019)., with a Cronbach alpha coefficient in the current study of 0.92  
3.5.3 Decision Regret 
The Decision Regret Scale (Brehaut et al., 2003) was used to measure the subjective 
feelings participants had about their treatment choice. The scale is a valid and useful tool 
which indicates health care decision regret at any time point (Brehaut et al., 2003). Questions 
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required participants to think about the decision made surrounding treatment. Specifically, 
they were asked to rate their agreement with five statements: ‘It was the right decision’, ‘I 
regret the choice that I made’, ‘I would go for the same choice if I had to do it over again’, 
‘The choice did me a lot of harm’ and ‘The decision was a wise one’. The participant was 
asked to indicate their agreement on a scale of 1 (Strongly Agree) to 5 (Strongly Disagree). 
Items 2 and 4 (‘I regret the choice that I made’ and ‘The choice did me a lot of harm’) were 
reverse coded (O’Connor, 1996). The score was converted to a 0-100 scale by subtracting 1 
from each item and multiplying it by 25. To obtain the final score, the items were summed 
and averaged. As a result, a score of 0 indicated low regret and a score of 100 indicated very 
high regret (O’Connor, 1996). The Cronbach alpha coefficient in the current study was 0.87. 
3.5.4 Quality of Life  
Quality of Life (QOL) was measured using two instruments - the global health score 
of the EORTC QLQ-C30 (Aaronson et al., 1993; Ayana, Negash, Yusuf, Tigeneh, Haile, 
2016; Kaasa et al., 1995) and the EQ-5D (EuroQol Research Foundation, 2018), both of 
which have been commonly used to assess the QOL of cancer survivors and both of which 
are valid scales (Nicklasson & Bergman, 2007; Obradovic, Lal, & Liedgens, 2013). 
Investigating the relationship between QoL and regret was one of the central aims of the 
current study, and while the EORTC QLQ-C30 and the EQ5-D measure the same 
phenomenon, they do so in different ways. The rationale for including both measures in the 
study was intended to give a more comprehensive understanding of the specific aspects of 
participants’ QoL and to provide more opportunity to investigate their relationship with 
regret.  
Firstly, participants were asked to indicate how they rated their physical wellbeing 
and quality of life in the past month, using a scale ranging from 1 (very poor) to 7 (excellent). 
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Following guidelines, an average of the measures of perceived physical condition over the 
past month and perceived QoL over the past month was computed to gain a global health 
score. Secondly, using the EQ5D, participants were asked to indicate whether they 
experienced any problems associated with their mobility, self-care, usual activities (work, 
study, housework, leisure, or family activities), pain/discomfort and anxiety/depression on the 
day of the survey. Responses allowed participants to report no problems, or a slight, 
moderate, severe, or extreme problem in each of the domains. The answers were firstly coded 
by assigning a number to each answer ranging from 1 (I have no problem with…) to 5 (I have 
an extreme problem with…). Following an established procedure (EuroQol Research 
Foundation, 2018), the scores were further simplified into a binary variable with 0 indicating 
no problem with an aspect of well-being and 1 indicating some problem (ranging from slight 
to extreme). 
3.5.5 Social Support and Support Services 
This section of the survey was concerned with the subjective experience of the social 
support received by the participant before, during and after treatment. Measures were taken 
from The SuN Study (SuN study - Supportive care needs of survivors of head & neck cancer: 
O’Brien et al., 2017). Participants were asked to indicate how satisfied they were with the 
support they received from the people in their life at three time points: (1) while making the 
decision about their treatment, (2) during their treatment and (3) currently (i.e. at the time of 
survey completion). To do this, participants were asked to rate their agreement with the 
statements on a scale of 1 (strongly agree) to 6 (strongly disagree). These scores were treated 
as single items. 
Participants were also asked whether they had used online or other support services 
since their diagnosis, when exactly they had used them (before, during or after treatment), 
66 
and whether they felt the support service provided them with the help they needed (yes or no) 
(O’Brien et al., 2017).  
3.5.6 Positive Psychological Appraisals 
Participants’ optimism, resilience, purpose and autonomy were measured by items 
from the 4th European Quality of Life Survey (Eurofund, 2017). Participants were asked to 
indicate their level of agreement with five statements: ‘I am optimistic about my future’, ‘I 
generally feel that what I do in life is worthwhile’, ‘I feel I am free to decide how to live my 
life’, ’I find it difficult to deal with important problems that come up in my life’ and ‘When 
things go wrong in my life, it generally takes me a long time to get back to normal’. Items 
were rated in a scale of 1 (strongly agree) to 5 (strongly disagree). The last two statements 
measured resilience and as they were negatively framed, were reverse coded for the purpose 
of the analysis. The resilience score was computed by averaging responses to these questions, 
while the other items were treated independently as per the user manual. 
The last question of the survey included an open-text answer box where participants 
were given the opportunity to add further comments. The question used here was: “Is there 
anything else you would like to add?”.  There was no word limit, so participants were free to 
discuss any other aspects of their illness/treatment/survivorship or to provide information 
which they felt they had not been asked about throughout the survey. 
3.5.7 Ethical considerations 
The participants were individuals who had undergone treatment for cancer or who had 
already initiated treatment (e.g., hormone therapy). As such the participants may have been 
classed as vulnerable as they were cancer survivors, i.e., they had experienced a cancer 
diagnosis and treatment process and were no longer classed as cancer patients. As the study 
asked participants to answer questions regarding their experience of cancer diagnosis, 
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treatment decision making, the treatment itself and their current quality of life, there was a 
risk of distress being caused by these questions with potential for this to invoke negative 
emotions linked to the participants’ experience of cancer. However, studies which require 
participants to provide information about their cancer diagnosis, treatment and well-being are 
plentiful, and have given important insight into the experiences of cancer patients with 
minimal ethical risk (Drummond, Gavin, & Sharp, 2018; O’Brien et al., 2017; Blanchard, 
Labrecque, Ruckdeshel, & Blanchard, 1988; Ashbury, Findlay, Reynolds, & McKerracher, 
1998). The risk in this study was mitigated further by involving cancer survivors only and not 
current cancer patients. On completion of the survey, participants were provided with contact 
information of the Irish Cancer Society. 
Ethical approval was gained from the Maynooth University Ethic Committee on the 
14th of December 2018, reference number: SRESC-2018-139 (Appendix E).  
3.6 Procedure 
Following ethical approval, the survey was published on Qualtrics in January 2019. 
The online survey link revealed an information sheet (Appendix F) which contained a 
detailed explanation of the study. It explained the right to refuse participation or withdraw 
from the research at any point and for any reason. It also provided the participants with 
contact details for the researcher and the supervisor, in case more questions needed to be 
answered before the study commenced. The information sheet held details of an appropriate 
support groups which could be contacted if participants felt distressed following the research. 
The same information appeared at conclusion of the survey. The consent form (Appendix G) 
was presented after the information sheet and ensured the participants met the inclusion 
criteria. Participants were asked to tick each statement which confirmed their consent and to 
tick each statement which confirmed their eligibility (according to the inclusion criteria). If 
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any of the statement were not ticked, the participants were not able to access the survey. 
Instead, they were taken to the final page and thanked for their willingness to participate. 
Unfortunately, the printed survey allowed for access without an appropriate completion of the 
consent form. However, all of the paper consent forms were filled out appropriately. 
Participant recruitment occurred in different stages due to an unsatisfactory number of 
survey responses within the first month. Based on the number of variables intended to be 
used in the model, the initial goal sample size was 150 and every effort was made to recruit 
as many participants as possible. The initial plan for participant recruitment was an online 
search to recruit using online cancer support groups and social media. In January 2019, the 
survey was posted on cancer related Facebook pages and forums (with the permission of the 
administrators) and shared via social media. At the same time, an email containing details of 
the study and a link to the survey was sent to Irish cancer support groups, including the Irish 
Cancer Society, with a request to disseminate to their members. Those support groups which 
did not respond via email, were contacted by phone with a follow-up request. A number of 
support groups agreed to distribute the survey link amongst their service users. In addition to 
the survey link distribution, various hospitals and GP clinics were visited and contacted via 
email with a request of displaying a poster designed to advertise the study. The poster 
contained a link to the survey along with a QR code, which can be scanned with a phone 
camera allowing instant access to the survey. As this did not yield sufficient results, another 
step in the participant recruitment process was taken. In April 2019, the survey was printed 
and copies of it were distributed amongst local support groups with a request to pass them 
onto interested cancer survivors. The surveys were anonymous and were mailed back to the 
researcher. The survey was finally closed in October 2019. 
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3.6.1 Data analysis 
The results of all of the surveys were transferred from Qualtrics into IBM SPSS 25. 
The data were coded and analysed in the following ways: 
• To describe the characteristics of the sample (objective 1), and to understand the 
experiences of decision making in relation to cancer treatment (objective 2), 
descriptive statistics (e.g. means, standard deviations, frequencies) were calculated for 
all variables. 
• To explore the associations between decisional regret and sociodemographic, health, 
decision making, and psychosocial factors (objective 3), correlation analyses were 
conducted on all survey scales and the DRS scores. Pearson’s r was used where 
parametric assumptions had not been violated, and Spearman’s rho where they had. 
• To further meet objective 3, a hierarchical regression analysis was conducted to 
explore the relationship between decision regret and nine predictor variables. These 
variables were chosen based on theory and univariate correlations found in the 
previous analysis. The hierarchical multiple regression analysis was performed to 
assess (1) the ability of support satisfaction (at time of survey) and levels of SDM, 
and (2) the ability of health and psychological variables (global health score, 
optimism, purpose, autonomy and resilience) to predict levels of regret, after 
controlling for gender and ease of making ends meet, both of which were found to be 
significantly related to regret in the correlational analysis. Preliminary analyses 
indicated no serious violations of the assumptions of normality, linearity, 
multicollinearity and homoscedasticity.  
• Finally, to contribute to objective 2 (i.e. understand the experiences of decision 
making), a qualitative analysis of the open-text box responses was conducted using a 
thematic analysis approach. The analysis was conducted in five phases: data 
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familiarisation, initial code generation, searching for themes, reviewing and refining 
themes and theme definition and labelling (Braun & Clarke, 2006). Familiarisation 
occurred at the beginning of data analysis when interaction with the responses 
occurred but further immersion occurred when the data was repeatedly read while 
actively searching for reoccurring themes and patterns (Braun & Clarke, 2006). From 
the list of ideas generated during familiarisation, codes or basic segments were 
extracted in order to organise the data into meaningful groups (not as broad as final 
analysis themes) (Braun & Clarke, 2006). The long list of codes was then scanned to 
find potential general themes. Those themes were then refined, defined and named. 
3.7 Patient and Public Involvement 
In June 2020, after results of Study 1 and Study 2 were analysed, feedback was sought 
from Irish cancer survivors as to their observations on the findings. This was done as a way 
of validating the results by individuals who have experienced the cancer treatment decision 
making, the treatment itself and its aftermath. Survivors were contacted through Irish cancer 
support groups or encouraged to deliver feedback on social media platforms. A brief 
summary of results was presented in PDF format, along with a visual depicting of findings as 
presented in poster format at a national conference (Appendix H). The survivors who wished 
to take part filled out a brief Qualtrics survey (Appendix I) which asked whether they relate 
to the findings of the systematic review and the cross-sectional study, or whether they feel 
some aspects of survivorship omitted in results. Specifically, cancer survivors were asked the 
following:  
• If you have any opinions on the findings of this project, please comment on these 
below.  
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• Is there any aspect of cancer survivorship, especially in relation to regret, that may 
have been missed in this study?  
• Do you relate to the findings of this study in any way?  
• Do you feel like these findings have any implications for the care of cancer survivors? 
If so, please comment on what these implications might be.  
• If there is anything else you would like to comment on, please do so below.  
The survivors were also given the opportunity to contact the researcher directly and to 
provide feedback through email. The participants were given an open-text response boxes 
and were free to provide any feedback they felt was relevant. Nine responses were collected 
from four males and five females. Further details of the feedback achieved can be found in 
Chapter 6. 
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Chapter 4 
Study 2 - An Analysis of the Factors Associated with Post-Treatment Regret in Cancer 
Survivors Living in Ireland - Results 
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4.1 Descriptive Statistics 
4.1.1 Sociodemographic and Background Information 
 101 participants took part in the survey but just 92 participants were included in the 
final analysis, with the remaining 9 excluded due to large amounts of missing data. The 
sample compromised of male (n = 33) and female (n = 59) cancer survivors aged between 19 
and 85 years (M= 55.62, SD = 15.28). The majority of the participants were Irish (95.7%, n = 
88), had no dependent children (69.6%, n = 64) and were married or co-habiting with a 
partner (71.7%, n = 66). Exactly half of the participants described their highest education 
level achieved as secondary school or lower (n = 46), with the other half having attained a 
third level degree or higher (n = 46). 54.3% of the participants were not working at the time 
of the survey (n = 50), and 57.6% reported no employment status change since cancer 
diagnosis. 12% of the participants provided unpaid personal help to a relative (n = 11). Most 
participants reported an ease of making ends meet (M = 2.98, SD = 1.15). 21.7% of the 
participants also reported another chronic health condition (n = 20), with the most common 
being diabetes (n = 3) and asthma (n = 3). Details of the socio-demographic and background 
information can be found in Table 5 (categorical variables) and later Table 8 (continuous 
variables). 
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Table 5 
Details of categorical socio-demographic and background information of the participants 
 
Variable N Percent 
Gender Identity Male 33 35.9 
Female 59 64.1 
Nationality Irish 88 95.7 
Other 4 4.3 
Dependent children Yes 27 29.3 
No 65 69.6 
Marital Status Married/co-habiting 26 28.3 
Other 66 71.7 
Education level Secondary or lower 46 50 
Third level or higher 46 50 
Employment status Working 42 45.7 
Not working 50 54.3 
Employment change  
since diagnosis 
Yes 38 41.3 
No 53 57.6 
Caring responsibilities Yes 
No 
11 
81 
12 
88 
Chronic health conditions Yes 20 21 
No 72 79 
 
4.1.2 Cancer Type, Treatment and Health Information 
Participants’ cancers were of varying types, with 23 different types being reported. 
The two most common were breast cancer (47.8%, n = 44) and prostate cancer (16.3%, n = 
11) but also testicular cancer (n = 5), bowel cancer (n = 5) and Non-Hodgkin’s lymphoma (n 
= 3). The prevalence of all of the cancer types can be seen in Table 6 below. Time since 
diagnosis ranged from 1 to 22 years (M = 6.97, SD = 4.92). The treatment reportedly 
occurred between 6 months and 22 years ago (M = 6.5, SD = 4.92), with 13% (n = 12) of the 
participants reporting that their treatment was ongoing at the time of survey completion 
(medication/hormone therapy). Treatment types undertaken varied. While the participants 
were asked to report on their primary treatment, most gave details of all of the treatment 
undertaken, details of which can be seen in Table 7 below. The participants availed of either 
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one or a combination of the treatments. The most common forms of treatment were surgery 
(including colectomy, hysterectomy, lumpectomy, mastectomy, prostatectomy, removal of 
ovaries; n = 35), radiation (n = 35), and chemotherapy (n = 34). 
Table 6 
The frequency of all cancer types reported by participants in the study 
 
 
Cancer Type Frequency Percent 
Acute myeloid leukaemia  2 2.2 
Bladder 1 1.1 
Bowel 5 5.4 
Breast 44 47.8 
Cholangiocarcinoma 1 1.1 
Chronic lymphocytic leukaemia 1 1.1 
Colorectal 2 2.2 
Hodgkin’s lymphoma 1 1.1 
Kidney 1 1.1 
Laryngeal 1 1.1 
Leukaemia 1 1.1 
Liver 1 1.1 
Lung 1 1.1 
Melanoma 2 2.2 
Myeloma 1 1.1 
Neuro Endocrine Tumours 1 1.1 
Non-Hodgkin’s lymphoma 3 3.3 
Non-melanoma skin 1 1.1 
Ovarian 1 1.1 
Prostate 15 16.3 
Testicular 5 5.4 
Waldenstrom's Macroglobulinemia 1 1.1 
Womb 1 1.1 
Total 93*  100 
* One patient reported two types of cancer 
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Table 7 
The frequency of cancer treatments availed of by the participants 
   
Treatment type Frequency Percent 
Active monitoring 1 .7 
Active surveillance 3 2.1 
Biopsy 1 .7 
Brachytherapy 2 1.4 
Chemotherapy 34 23.4 
Colectomy 1 .7 
External beam radiation 2 1.4 
Hormone therapy 5 3.4 
Hysterectomy 1 .7 
Lumpectomy 5 3.4 
Mastectomy 11 7.6 
Medication 11 7.6 
Prostatectomy 1 .7 
Radiation 33 22.8 
Radiofrequency ablation 1 .7 
Removal of ovaries 1 .7 
Resection 1 .7 
Sandostatin injection 1 .7 
Surgery (other) 29 20.0 
Targeted therapy 1 .7 
Total 145 100.0 
* 41 patients reported more than one type of treatment undertaken 
4.1.3 Current Health Status and Quality of Life 
Participants generally reported high levels of wellbeing using the global health score 
of the QLQ-C30 (M = 5.52, SD = 1.42). At the time of survey completion, using the EQ5D, 
most of the sample reported no problems with mobility, self-care activities, difficulty with 
usual activities, pain/discomfort and anxiety or depression. However, 38% of participants 
reported some problem with pain and discomfort and 32% reported problems with depression 
and anxiety. A breakdown of the frequency of problems reported with the five variables is 
presented in Figure 2. 
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Figure 2  
Percentage of participants who reported having no problem vs. having some problem with 
mobility, self-care, usual activity, pain and discomfort, anxiety and depression 
 
4.1.4 Information on the Decision Making Process 
52.% of participants reported that they were given more than one treatment option, 
compared to 30.4% who advised only one treatment option was available and 17.4% who 
were unsure. 65.2% (n = 60) of the sample spoke to someone other than the doctor about their 
diagnosis and treatment options but only 17.4% (n = 16) sought a second medical opinion. 
76.1% (n = 70) of participants felt they had enough time to make a treatment decision, 
implying that almost 25% felt they did not have enough time. 29.3% (n = 27) of the sample 
reported that the possibility of side effects strongly affected their decision, 28.3% (n = 26) 
felt this affected their decision slightly and 42.4% (n = 39) felt the possibility side effects did 
not affect their decision at all. 45.7% (n = 42) of participants reported seeking information 
about their diagnosis and treatment online, with the majority reporting not spending a lot of 
time conducting this information search (M = 2.49, SD = 2.93). An illustration of this 
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information can be found in Figure 3 below. Most participants felt more informed at the time 
of the survey (M = 5.92, SD = 1.42), than at the time of the treatment decision (M = 4.56, SD 
= 1.97).  
Figure 3  
Percentage of participants who agreed to survey items asking about their decision making 
process 
 
Scores on the SDM scale ranged from 0 to 100 (M = 32.39, SD = 24.34), with 0 
indicating high perceived SDM. 75% (n = 69) of the participants scored below 50 on the 
SDM-Q-9, indicating that perceived SDM was high in the majority of the sample. 14.1% (n = 
13) of the sample scored 0 and indicated very high levels of shared decision making in their 
experience, while 6.6% (n = 6) of the sample scored above 75 indicating very low levels of 
shared decision making. One participant (1.1%) scored 100 and indicated that no shared 
decision making took place. 
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4.1.5 Social Support and Support Services 
Satisfaction with social support was high before (M = 1.42, SD = 0.93), during (M = 
1.39, SD = 0.9) and after treatment (M = 1.66, SD = 1.09). Online support services were used 
by 30.4% (n = 28) of participants, while face-to-face support services were used by 43.5% (n 
= 40) of participants. Online support services were used by 10.9% (n = 10) of participants 
before treatment, 17.4% (n = 16) during treatment, 17.4% (n = 16) after treatment and 12% (n 
= 11) at the time of the survey. 10.9% (n = 10) of those who used online support services 
found them useful to a great extent, 16.3% (n = 15) found them useful to some extent and 
2.2% (n = 2) did not find them useful at all. Other support services were used by 8.7% (n = 8) 
before treatment, 28.3% (n = 26) during treatment, 21.7% (n = 20) after treatment and 12% (n 
= 11) at the time of the survey. 20.7% (n = 19) of those who used other support services 
found them useful to a great extent, 18.5% (n = 17) found them useful to some extent and 
3.3% (n = 3) did not find them useful at all. 
4.1.6 Positive Psychological Appraisals 
Overall, the participants displayed high levels of positive psychological appraisals, 
with the majority of participants displaying high levels of optimism (M = 4.21, SD = .99), 
purpose (M = 4.37, SD = 0.83), autonomy (M = 4.5, SD = .75) and resilience (M = 3.62, SD 
= 1.23).  Details of all continuous variables in the study can be found in Table 8 below. 
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Table 8  
Details of continuous variables in the study 
Variable M SD Observed Range 
Age 55.62 15.28 19-85 
Ease of making ends meet 2.98 1.15 1-6 
Time since diagnosis 6.97 4.78 1-22 
Time since treatment 6.5 4.92 0.5-22 
Time spent seeking information online 2.49 2.93 0-7 
Feeling well-informed at the time of 
treatment decision 
4.56 1.97 1-7 
Feeling well-informed at the time of survey 5.92 1.42 1-7 
Score on the SDM-Q-9 32.39 24.34  0-100 
Score on the DRS 21.73         23.4            0-100 
Global health score 5.52 1.42 1.5-7 
Optimism 4.21 .99 1-5 
Purpose 4.37 .83 1-5 
Autonomy 4.5 .75 1-5 
Resilience 3.62 1.23 1-5 
 
4.1.7 Decision Regret Score 
Overall, levels of decision regret were low amongst participants, with a mean DRS 
score of 21.79 (SD = 23.4). 73% (n = 68) of the sample scored below 30 on the DRS and this 
is considered a low score (Becerra-Perez, Menear, Turcotte, Labrecque, & Légaré, 2016). 
Only 11.96% (n = 11) of the sample scored above 50 on the DRS and this is considered a 
high score (Maguire, Hanly, Drummond, Gavin, & Sharp, 2017).  
4.2 Correlation Analyses  
 4.2.1 Relationships Between Sociodemographic Factors and Regret 
 Correlation analysis was conducted between all variables with a focus on how these 
related to decisional regret (see Table 9). Gender identity had a weak positive relationship 
with the scores on the DRS (r = 0.283, p < 0.01), suggesting that females were more likely to 
experience regret than males. An independent-samples t-test confirmed this, with a 
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significant difference in DRS found between males (M = 15, SD = 21.25) and females (M = 
25.59, SD = 23.85) (t (90) = -2.12, p < 0.05).  
A positive moderate relationship was found between the measure of financial status 
and scores on the DRS (r = 0.363, p < 0.01), indicating that those who reported difficulty 
with making ends meet were more likely to experience regret. Scores on the DRS were not 
significantly correlated with age, nationality, children, marital status, education level, 
employment status, the provision of caring responsibilities or presence of other chronic health 
conditions. 
4.2.2 Relationships Between Treatment Types and Regret 
In Chapter 2, many studies investigated the prevalence of regret with different 
treatment types. Given the range of different treatment types available, and the small number 
of participants reporting some treatments, it was not possible to compare regret levels across 
the entire sample. However, a pattern emerged across the participants who scored 50 or above 
on the DRS (n = 11). The majority of those participants reported undertaking surgery as part 
of their treatment (n = 9), with some participants undertaking surgery only (n = 6), and some 
also availing of a combination of other treatments (n = 3). 
4.2.3 Relationships Between the Decision Making Process and Regret 
A number of aspects of the decision making process were found to have a significant 
relationship with DRS scores. There was a moderate positive relationship between perceived 
satisfaction with the time to decide on a treatment and DRS scores (rs = 0.475, p < 0.01), 
suggesting that those who felt they did not have adequate time to decide on a treatment felt 
more regret. There was a moderate negative relationship between the perceived effect of 
possible side effects on the decision and the DRS scores (rs = -0.398, p < 0.01), indicating 
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that those who felt side effects affected their decision also felt more regret. A moderate 
positive relationship was found between the time spent seeking information (relating to the 
treatment) online and the scores on the DRS (rs = 0.254, p < 0.05). Those who reported 
spending more time seeking information reported higher levels of regret, perhaps suggesting 
that searching for information online is not helpful (or maybe is indicative of the lack of 
satisfactory information found). A weak negative relationship was found between how 
informed participants felt at the time of their treatment decision and the scores on the DRS (rs 
= -0.216, p < 0.05). A moderate negative relationship was found between how informed 
participants felt at the time of the survey and the scores on the DRS (rs = -0.328, p < 0.01). 
These results indicate that a low perceived level of information about the cancer treatment 
both at the time of the decision and post-treatment correlated with decision regret. Lastly, a 
strong positive relationship was found between scores on the SDM scale and scores on the 
DRS (rs = 0.537, p < 0.01), indicating that participants who reported a lower level of shared 
decision making also reported more regret. 
4.2.4 Relationships Between Health Status and Quality of Life and Regret 
There was a moderate negative relationship between global health scores and DRS 
scores (rs = -0.417, p < 0.01), indicating that the better perceived quality of life reported by 
the participants, the lower their regret. Similar results were found in the analysis of the EQ5D 
scores and DRS scores, with all variables (mobility, usual activity, pain and discomfort, 
anxiety and depression) except self-care having a weak to moderate positive relationship with 
DRS. Details of effect sizes and significance values are shown in Table 9 below. This 
indicates that participants who reported problems with mobility, usual activity, pain and 
discomfort and anxiety and depression also reported higher levels of regret.  
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4.2.5 Relationships Between Social Support and Regret 
The results of the correlation analysis between support-related scales and scores on 
the DRS indicate the importance of social support. Moderate positive relationships were 
found between satisfaction with social support before (rs = 0.305, p , 0.01), during (rs = 0.307, 
p , 0.01) and after  (rs = 0.337, p < 0.01) treatment and the scores on the DRS, suggesting that 
those who were satisfied with the social support received experienced less regret. However, 
the same results were not found in the analysis of the relationship between support service 
use and regret. Weak negative relationships were found between the use of support groups, 
both on- (rs = -0.241, p < 0.05) and offline (rs = -0.207, p < 0.05), and the scores on the DRS. 
This indicates that those who reported using online and other support services were also more 
likely to experience regret.  
4.2.6 Relationships Between Positive Psychological Appraisals and Regret 
Moderate to strong negative relationships were found between DRS scores and 
optimism (rs = -0.406, p < 0.01), purpose (rs = -0.317, p < 0.01), autonomy (rs = -0.366, p < 
0.01) and resilience (rs = -0.442,  p < 0.01). These results suggest that those who are less 
optimistic, have less autonomy, purpose and resilience also reported higher regret. 
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Table 9 Correlation matrix of all variables included in study  
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 
1. DRS score [higher 
= more regret] 
1                        
2. Gender Identity 
[male = 0; female = 1] 
-
.283
** 
 
1 
                      
3. Income [higher = 
difficulty in making 
ends meet] 
 
.459
** 
 
.115 
 
1 
                     
4. Enough time to 
make decision [yes = 
0; no =1] 
 
.475
** 
 
.154 
 
.272
** 
 
1 
                    
5. Decision affected 
by possibility of side 
effects [lower=more 
likely] 
-
.398
** 
-
.106 
-
.229
** 
-
.268
** 
 
1 
                   
6. Time spent seeking 
info online [higher = 
more time] 
 
.254
** 
 
.201 
-
.015 
 
.093 
-
.446
** 
 
1 
                  
7. Feeling well-
informed at the time 
of decision [higher = 
better informed] 
-
.216
** 
-
.002 
 
.107 
-
.329
** 
 
.045 
 
.226
* 
 
1 
                 
8. Feeling well-
informed at the time 
of survey [higher = 
better informed] 
-
.328
** 
-
.095 
-
.337
** 
-
.178 
-
.072 
 
.164 
 
.269
* 
 
1 
                
9. SDM-Q-9 score 
[higher = less SDM] 
 
.537
** 
 
.251
* 
 
.336
** 
 
.544
** 
-
.242
* 
 
0.73 
-
.251
** 
-
.31** 
 
1 
               
10. Global Health 
Score [higher = better 
perceived well-being] 
-
.417
** 
-
.095 
-
.37** 
-
.385
** 
 
.134 
-
.193 
 
.121 
 
.351
** 
-
.288
** 
 
1 
              
11. Support before 
treatment [satisfied = 
0; not satisfied = ] 
 
.305
** 
 
.048 
 
.197 
 
.255
* 
-
.095 
-
.061 
-
.085 
-
.284
** 
 
.117 
-
.226
* 
 
1 
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12. Support during 
treatment  [satisfied = 
0; not satisfied = 1] 
 
.307
** 
 
.137 
 
.269
* 
 
.041 
-
.095 
. 
196 
 
.033 
-
.310
** 
 
.184 
-
.283
* 
 
.261
* 
 
1 
            
13. Support current 
[satisfied = 0; not 
satisfied = 1] 
 
.337
** 
-
.078 
 
.197 
 
.162 
-
.136 
-
.024 
-
.213
* 
-
.197 
 
.177 
-
.36** 
 
.375
** 
 
.199 
 
1 
           
14. Use of online 
support services [yes 
= 0; no = 1] 
-
.241
* 
-
.347
** 
 
-.05 
-
.072 
. 
066 
-
.481
** 
-
.212
* 
 
.035 
-
.008 
 
.381
** 
-
.091 
-
.145 
-
.112 
 
1 
          
15. Use of other 
support services [yes 
= 0; no = 1] 
-
.207
* 
-
.199 
-
.101 
 
.029 
-
.133 
-
.155 
-
.174 
 
.184 
-
.061 
 
.246
* 
 
.079 
-
.209
* 
 
.054 
 
.278
** 
 
1 
         
16. Optimism [higher 
= more optimism] 
-
.406
** 
 
-.04 
-
.296
** 
-
.333
** 
 
.044 
 
.117 
 
.249
* 
 
.331
** 
-
.402
** 
 
.524
** 
-
.279
** 
-
.176 
-
.337
** 
 
.065 
 
.008 
 
1 
        
17. Purpose [higher = 
more purpose] 
-
.317
** 
 
.062 
-
.303
** 
-
.284
** 
 
.034 
 
.111 
 
.134 
 
.343
** 
-
.371
** 
 
.421
** 
-
.184 
-
.093 
-
.344
** 
. 
013 
 
.047 
 
.733
** 
 
1 
       
18. Autonomy [higher 
= more autonomy] 
-
.366
** 
 
.085 
-
.376
** 
-
.281
** 
 
.006 
 
.095 
 
.198 
 
.302
** 
-
.366
** 
. 
321*
* 
-
.249
* 
-
.142 
-
.309
** 
-
.001 
 
.12 
 
.668
** 
. 
68** 
 
1 
      
19. Resilience [higher 
= more resilience] 
-
.442
** 
 
.129 
-
.124 
-
.276
** 
 
.192 
-
.123 
 
.288
** 
 
.327 
-
.388
** 
 
.234
* 
 
-.17 
-
.074 
-
.236
* 
 
.146 
 
.018 
 
.343
** 
 
.455
** 
 
.391
** 
 
1 
     
20. Mobility [higher = 
more problem] 
 
.294
** 
 
.028 
 
.216
* 
 
.241
* 
-
.065 
-
.148 
-
.068 
-
.267
* 
 
.221
* 
-
.616
** 
 
.217
* 
 
.206
* 
 
.351
** 
-
.149 
-
.055 
-
.612
** 
-
.451
** 
-
.408
** 
-
.103 
 
1 
    
21. Self-care [higher = 
more problem] 
 
.139 
-
.121 
 
.149 
-
.012 
 
.032 
-
.140 
-
.034 
-
.124 
 
.024 
-
.376
** 
-
.063 
 
.130 
 
.188 
 
.053 
 
.060 
-
.334
** 
-
.335
** 
-
.288
** 
 
.057 
 
.533
** 
 
1 
   
22. Usual Activity 
[higher = more 
problem] 
 
.405
** 
 
.138
. 
 
.232
* 
 
.165 
 
.007 
-
.041 
-
.062 
-
.336
** 
 
.250
* 
-
.760
** 
 
.229
* 
. 
302
** 
 
.434
** 
-
.321
** 
-
.220
* 
-
.586
** 
-
.419
** 
-
.414
** 
-
.160 
 
.731
** 
 
.350
** 
 
1 
 
. 
 
23. Pain/ Discomfort 
[higher = more 
problem] 
 
.353
** 
 
.189 
 
287
** 
 
.288
* 
-
.054 
-
.031 
-
.072 
-
.322
** 
 
.336
** 
-
.672
** 
 
.393
*** 
 
.308
** 
 
.398
** 
-
.289
** 
-
.090 
-
.602
** 
-
.430
** 
-
.387
** 
-
.130 
 
.781
** 
 
.362
** 
 
.753
** 
 
1 
 
24. Anxiety/ 
Depression [higher = 
more problem] 
.507
** 
.156 .217
* 
.351
** 
-
.109 
.241
* 
-
.144 
-
.411
** 
.429
** 
-
.596
** 
.247
* 
.464
** 
.513
** 
-
.435
** 
-
.194 
-
.446
** 
-
.412
** 
-
.319
** 
-
.331
* 
.315
** 
.382 .490
** 
.480
** 
1 
Statistical significance: *p < .05; **p < .01 
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4.3 Regression analysis 
Hierarchical multiple regression analysis was performed to assess (1) the ability of 
support satisfaction (at time of survey) and levels of SDM, and (2) the ability of health and 
psychological variables (global health score, optimism, purpose, autonomy and resilience) to 
predict levels of regret, after controlling for gender and ease of making ends meet, both of 
which were found to be significantly related to regret in the correlational analysis.  The 
number of variables included in the model was led by consideration of statistical power and 
their nature was led by the study aims - to explore the associations between 
sociodemographic, health, decision making, and psychosocial factors and the experience of 
decisional regret. More specifically, the key goal of the study was to examine how (1) aspects 
of the decision making process, and (2) psychosocial factors, influenced regret, after 
controlling for known sociodemographic associates. It is for this reason that a hierarchical 
regression analysis was deemed the most suitable analytic approach for investigating this. 
The regression model can be found in Table 10 below. 
Preliminary analyses indicated no serious violations of the assumptions of normality, 
linearity, multicollinearity and homoscedasticity. Gender and ease of making ends meet were 
entered at step 1, explaining 24.6% of variance in decisional regret. Ease of making ends 
meet was statistically significant at this step (β = .45, p < .001), suggesting that those who 
found it easier to make ends meet reported experiencing later regret. Support satisfaction at 
time of survey and SDM-Q-9 scores were entered at step 2 of the model, explaining 38.9% of 
variance in decisional regret. The variables entered at step 2 explained an additional 14.3% of 
variance (R squared change = .143, F change (2, 83) = 9.69, p < .001). Both social support 
satisfaction (β = .27) and SDM (β = .28) significantly predicted regret at this step. 
Significantly those reporting higher support satisfaction and a higher level of SDM were less 
likely to experience regret. After entry of global health score, optimism, purpose, autonomy 
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and resilience at step 3, the total variance explained by the model as a whole was 49.4% (F 
(9, 78) = 8.47, p = .01). The last 5 control measures explained an additional 10.6% of the 
variance in regret (R squared change = .106, F change (5,78) = 3.26, p < .001). In the final 
model, only three measures were statistically significant: global health score (β = -.28, p = 
.019), score on the SDM-Q-9 (β = .23, p = .019) and resilience (β = -.23, p = .011). Those 
with higher QoL scores, reporting greater SDM and higher resilience experienced less regret. 
A post-hoc power analysis was conducted. Given the sample size of 92, an alpha level 
of 0.05, a medium effect size (f2=0.15) and 9 predictors, the power of the model was 0.68. 
This suggests that the model was underpowered given the small sample size, which is a 
limitation of the study. 
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Table 10  
Hierarchical regression model 
 
 
 
Variables Β p t B SE 
Step 1       
Gender  .152 .115 1.594 7.365 4.621 
Income [higher = difficulty in making ends meet] .450*** .000 4.727 9.150 1.936 
R2 Change = .246       
Step 2       
Gender .132 .146 1.468 6.396 4.356 
Income [higher = difficulty in making ends meet] .261 .008 2.698 5.310 1.968 
Support satisfaction at the time of survey [satisfied = 0; not satisfied = 1] .270** .004 2.941 25.462 8.657 
SDM-Q-9 score [higher = less SDM] .280** .004 2.930 .269 .092 
R2 Change = .143        
Step 3        
Gender .059 .503   .673 2.854 4.241 
Income [higher = difficulty in making ends meet] .163 .130   1.531 3.323 2.170 
Support satisfaction at the time of survey [satisfied = 0; not satisfied = 1] .234 .071   1.833 17.197 9.380 
SDM-Q-9 score [higher = less SDM] .182* .019   2.399 .225 .094 
Global Health Score [higher = better perceived well-being] -.276* .019  -2.402 -4.538 1.889 
Optimism [higher = more optimism] .023 .880 .151 .536 3.548 
Purpose [higher = more purpose] .222 .104 1.645 6.274 3.815 
Autonomy [higher = more autonomy] -.165 .141 -1.488 -5.139 3.453 
Resilience [higher = more resilience] -.232* .011 -2.592 -4.406 1.700 
R2 Change = .106      
Adjusted R2 = .436      
*p<0.05, **p<0.01, ***p<0.001      
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4.4 Thematic analysis 
 The last question of the survey (“Is there anything else you would like to add”) was 
answered by 24 of 92 participants. A qualitative analysis of these responses was conducted 
using a thematic analysis approach.  The way in which the participants chose to answer this 
question can be described in two themes: ‘being thankful’ and ‘expressing dissatisfaction’. 
These themes will now be detailed and illustrated with exemplar quotes. 
 4.4.1 Theme 1: ‘Being thankful’ 
As the participants of the current study were cancer survivors, with only a number of 
them currently undergoing treatment in the form of medication, the theme of being thankful 
for their current health status was evident: ‘It’s good to be alive.’ (Participant 44, female, age 
71); ‘I feel lucky that the cancer was removed so quickly and with no complications.’ 
(Participant 88, male, age 77). The participants were also thankful for the medical staff: ‘I 
found my GP who knew me very well to be decisive and strongly suggested which consultant I 
should attend. I thank him for that regularly.’ (Participant 60, female, age 73); ‘Thank God 
for the doctors, consultants, nurses and thank God I got over the cancer.’ (Participant 35, 
male, age 76).  
The support received was also important to the participants: ‘While my future is 
uncertain my present is wonderful, thanks to the support I get.’ (Participant 19, male, age 72); 
‘I believe that the positive work of cancer support centres is a major asset in the recovery 
journey.’ (Participant 20, male, age 64); ‘Finding a local cancer support centre during my 
treatment was a lifeline to me. Being able to avail of counselling, support groups and 
complementary therapies at a very difficult time in my life was huge and most importantly 
meeting other cancer survivors was inspirational.’ (Participant 21, female age 41); ‘I was 
lucky to get counselling at St Luke’s for anxiety caused by my diagnosis. I had panic 
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symptoms sleep problems and I don’t know how I would have been without the counselling.’ 
(Participant 77, female, age 48).  
One participant displayed gratitude for the current research being conducted: ‘I am 
happy that someone is doing research into the psychological aspect of cancer survivorship.’ 
(Participant 10, female, age 47). 
 4.4.2 Theme 2: ‘Expressing dissatisfaction’ 
 Some participants voiced their dissatisfaction with various aspects of their journey 
through illness as well as their current health status. Some participants pointed out the lack of 
psychological support available: ‘At the time of my diagnosis I was not aware of emotional 
support. The front line medical treatment was excellent but psychological support was non-
existent.’ (Participant 3, male, age 64); ‘At the time of my illness and treatment there was very 
little support in my area except in St Luke's in Dublin where I completed my radiotherapy. 
Nothing local.’ (Participant 30, female, age 71).  
 Many participants expressed their regret about not being involved enough in their 
treatment decision making: ‘I feel I wasn't really given a choice in my treatment was just told 
what was going to happen because the cancer was advancing and everything was happening 
really quickly.’ (Participant 24, female, age 48); ‘I wish I was more involved when choosing 
my treatment but it all happened too fast and I trusted the specialists.’ (Participant 33, male, 
age 32); ‘Not enough time given at initial consultation when diagnosed. Felt rushed into 
decision. Difficult to make decision which goes against conventional approach.’ (Participant 
41, female, age 63). Some participants reported the negative side effects of their cancer 
treatments: ‘The chemotherapy has destroyed me.’ (Participant 22, female, age 56); ‘The 
surgery left me with visible scarring which I found difficult to accept for many years.’ 
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(Participant 36, female, age 28); ‘Chemo given even when it interferes with quality of life.’ 
(Participant 41, female, age 63). 
 A number of participants voiced their dissatisfaction with the health-care 
professionals: ‘I wasn’t provided with full or adequate information by my doctors. I struggle 
now as a result.’ (Participant 78, female, age 52); ‘My surgeon arrived up at the bed and 
said, "It’s amazing what a hissy fit will do". On the day I was being discharged I felt she had 
no interest in me or my recovery. I saw her once after that.’ (Participant 12, female, age 47).  
4.5 Conclusion 
 The results of the current study inform us of the strength of the relationships between 
a number of factors and regret in cancer patients. Significantly, cancer survivors who 
reported more SDM, higher QoL scores and higher resilience also report lower levels or 
regret. This result is mirrored in the qualitative analysis of the open-text responses, where 
participants discussed their experiences of decision making, physical and psychological 
wellbeing and satisfaction with support received. Further discussion of these results can be 
found in Chapter 5.  
 Ten cancer survivors were presented with the results of this study as well as the 
results of the systematic review in Chapter 2. Their feedback is discussed in Chapter 6. 
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Chapter 5 
Study 2 - An Analysis of the Factors Associated with Post-Treatment Regret in Cancer 
Survivors Living in Ireland - Discussion
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5.1 Overview 
The current study had three core objectives: 
1. To describe the characteristics of a sample of Irish cancer survivors who have 
undergone treatment. 
2. To understand the experiences of decision making in relation to cancer treatment. 
3. To explore the associations between sociodemographic, health, decision making, and 
social factors and the experience of decisional regret. 
  Results uncovered a number of interesting findings relating to the experience of 
cancer survivors in Ireland.  Findings highlight both the positive and negative aspects of life 
after recovery from cancer and may encourage further research aimed at helping cancer 
survivors increase their physical and psychological wellbeing. Most importantly, findings 
show the important role of the treatment decision making process in survivor wellbeing and 
highlight the factors which are associated with the emergence of decisional regret in cancer 
survivors, thereby meeting the study objectives. In the following sections, these results are 
discussed in more detail. 
5.2 Characteristics of Sample 
The participants in this study were cancer survivors recruited through cancer support 
groups in Ireland. They reported a range of cancer types, cancer treatments, treatment 
decision-making processes, experiences of illness and feelings post-treatment. The study 
included participants of various ages who came from an array of socioeconomic 
backgrounds. Both negative and positive attitudes towards their cancer experience were 
reported – including different attitudes towards healthcare professionals, the treatment 
decision-making process and the social support received. This highlights the considerable 
diversity in the experiences of Irish cancer survivors. 
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The number of survivors included in the final analysis was 92. There was a slight gender 
imbalance in the sample as 64% were female and 36% were male. Studies suggest that males 
are more likely to develop cancer than females, despite a shorter life expectancy (Dorak & 
Karpuzoglu, 2012), suggesting that the sample was not quite in line with population norms. 
While 47.8% of the sample were breast cancer survivors, 16.3% were prostate cancer 
survivors. This is broadly consistent with the NCRI 2019 report (O’Connor et al., 2019) 
which shows that the majority of Irish female cancer survivors had breast cancer (35,125; 
23% of all cancer survivors), while the majority of Irish male cancer survivors had prostate 
cancer (39,539; 20% of all cancer survivors). The next most common cancer for both genders 
in Ireland is colorectal cancer (9,205 female, 11,420 male; 12% of all cancer survivors), 
similarly, in the current study the third most represented cancer type was bowel cancer (5.4% 
of participants). However, other common cancers were not well represented in the current 
study, e.g., melanoma skin, corpus uteri, or cervical cancers. This suggests that the sample 
may not be fully representative of Irish cancer survivors, however data captured experiences 
from a range of survivors with different sociodemographic backgrounds and treatment 
experiences. 
5.3 Experience of Regret 
Overall, levels of treatment-related regret amongst participants were low which mirrors 
the results of previous research (Karuturi et al., 2019; Shakespeare et al., 2017), and is also 
consistent with the findings of the systematic review described in chapter 2. The levels of 
regret in the current study varied, with the majority of participants experiencing no regret or 
very low levels of decisional regret. However, 11.96% of the participants scored over 50 on 
the DRS (0-100 scale), indicating that a small portion of the sample experienced greater 
regret about their cancer treatment than most. Despite the low number of survivors with high 
regret scores, research suggests that it is important to acknowledge the difficulties some 
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cancer survivors face, even after their illness. It has been found that regret can be long lasting 
with studies reporting regret in patients between 1 and 15 years post-treatment (Cusatis, 
Tecca, D’Souza, Shaw, & Flynn, 2020; Cuypers, Lamers, Kil, van de Poll-Franse, & de 
Vries, 2019; Taneja, 2017). Some studies report that regret levels remain stable over time 
(Martinez, Resnicow, Graff, Hamilton, & Hawley, 2015) while other show that regret 
increases with time post-treatment (Diefenbach & Mohamed, 2007). While the current study 
was unable to examine how regret may have changed over time, no relationship between 
regret and time since diagnosis was found in the analysis.  High levels of regret were evident 
in recently diagnosed survivors (1 year), as well as those who had been diagnosed as many as 
25 years ago. 
5.4 Sociodemographic and Health-related Risk Factors  
 Like other studies of this nature (Lavery et al., 2012; Resnick et al., 2013; Sheehan, 
Sherman, Lam, & Boyages, 2008), the analysis of sociodemographic correlates of regret in 
cancer survivors allows for a clearer understanding of who may be at risk of experiencing it. 
The current study initially found that females reported more treatment regret than males. 
However, gender did not remain as a significant predictor of regret in the regression analysis. 
It is possible that any gender differences that emerged between regret levels did so due to 
other factors like differences in QoL, psychological wellbeing or social support. For example, 
studies suggest that females often report lower wellbeing and QoL than males – this is true 
for cancer patients (Hagedoorn, Buunk, Kuijer, Wobbles, & Sanderman, 2000) and patients 
of other illnesses (Bisegger, Cloetta, Von Bisegger, Abel, & Ravens-Sieberer, 2005; Emery et 
al., 2004; Mrus, Williams, Tsevat, Cohn, & Wu, 2005). While the difference in regret levels 
between males and females was found, it is difficult to state whether this result mirrors other 
findings in literature. This is due to the large volumes of studies which concentrate on one 
cancer type only – typically breast and prostate cancer (Advani et al., 2019; Maguire, Hanly, 
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Drummond, Gavin, & Sharp, 2017). Studies of cancer types which affect both genders rarely 
investigate the difference between regret in males and females (Criswell, Owen, Thornton, & 
Stanton, 2016; Goepfert et al., 2017). Future research should explore this issue further as 
knowledge on gender differences in the experience of regret can be valuable to healthcare 
providers. Supports may also be tailored according to needs of each gender. 
Correlation analyses in the current study found that those who report difficulty in 
“making ends meet” reported higher levels of decisional regret. 31.5% of participants 
reported some level of financial difficulty, which highlights that this is a problem for a 
considerable number of cancer survivors. Financial status was also the only statistically 
significant variable at step one of the regression analysis, indicating its importance even when 
controlling for gender differences. Financial difficulty is often found to be associated with 
regret in cancer patients, including financial toxicity, which refers to problems related to the 
cost of medical care (Sangha et al., 2018; Sangha, Bossick, Coleman, Su, & Wegienka, 
2019). Financial difficulty and financial burden of treatment in cancer patients has also been 
linked with lower levels of social, physical and emotional wellbeing (Barbaret et al., 2017), 
lower HRQoL (Chen et al., 2018) and is even a higher risk factor for mortality (Ramsey et 
al., 2016). Some patients choose to not take prescribed medication as the cost is too high 
(Alice, Banegas, Tucker-Seeley, & Yabroff, 2017).  
It is important to note that the financial burden of a cancer diagnosis varies by country 
and depends on the level of financial aid provided by each government. In Ireland, a 
public/private healthcare system exists, with those on lower incomes less likely to be able to 
afford private health insurance which may limit their access to certain services (Murphy, 
Bourke, & Turner, 2020). While the HSE and voluntary hospitals are used by most cancer 
patients, some may opt to be treated in a private hospital where medical care must be covered 
by the patient or paid through their health insurance. The presence of additional costly 
97 
medical resources available to a smaller percentage of the Irish population creates an unfair 
divide between cancer patients (Johnston et al., 2019). Apart from private medical services 
not being available to those with financial difficulties, cancer patients with lower incomes 
may struggle with travelling to medical appointments or availing of support services which 
are not in close proximity, ensuring a healthy diet, which can often be more expensive, or as 
mentioned above buying prescribed medication. Financial difficulty may increase the risk of 
regret post-treatment as well as many other negative outcomes.  
The correlation between sociodemographic factors and regret, especially that of the 
link between regret and financial difficulties, should allow healthcare professionals to 
identify patients who are most at risk of experiencing this negative feeling. The findings may 
also aid the tailoring of supports accordingly, for example by ensuring people have access to 
appropriate supports and resources, and that they are not disadvantaged based on financial 
situation (Carrera, Kantarjian, & Blinder, 2018). 
A number of aspects of physical and mental health correlated with decision regret. 
Lower perceived health scores and perceived QoL scores as well as problems with mobility, 
usual activity, pain and discomfort, anxiety and depression had a relationship with regret in 
this study. In our sample, most survivors experienced a good QOL, however a substantial 
minority reported problems with usual activity, pain, anxiety and depression, suggesting 
ongoing need for support for these groups. As discussed previously, regret is considered to be 
a negative side effect of cancer treatment as it is often linked to lower QoL and HRQoL 
(Clark et al., 2001; Davidson et al., 2007). The significant association between the global 
health score (which tested quality of life) and scores on the DRS in the final regression model 
was therefore not surprising, as studies of oncology populations more often than not present a 
relationship between poor physical and psychological wellbeing and regret (Becerra Pérez, 
Menear, Brehaut, & Legare, 2016; Hoffman et al., 2017; van Stam et al., 2018). Poorer 
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physical wellbeing, which can reduce psychological wellbeing, can often also stem from side 
effects of the cancer or the treatments chosen (Christie et al., 2015). Survivors can experience 
side effects of cancer and treatment long after diagnosis – the treatment for one illness can 
cause other serious health-related issues. For example, androgen-deprivation therapy may 
result in higher risks of bone fractures, diabetes, dementia, coronary heart disease or sexual 
dysfunction in prostate cancer survivors (Nguyen, Lairson, Swartz, & Du, 2018). This again 
highlights the importance of healthcare professionals providing all necessary information to 
cancer patients, especially that of the negative side-effects of the illness and the chosen 
treatment. 
5.5 The Experiences of Decision Making Related to Cancer Treatment 
An important aim of this study was to understand survivors’ experiences of various 
aspects of the treatment decision- making process. In line with expectations, a number of 
aspects of the treatment decision-making process correlated with higher levels or regret: 
feelings of not having enough time to decide on a treatment, feeling like the possibility of 
side effects affected the treatment decision, more time spent seeking information online, a 
low perceived level of being informed before and after treatment and a lower level of shared 
decision-making. Score on the SDM-Q-9 (Simon et al., 2006) was also one of the only three 
significant predictors of regret in the regression analysis.   
From the qualitative analysis of the survey results, it is also evident that the treatment 
decision-making process as well as interactions with the healthcare professionals play a role 
in the overall experience of cancer survivors, which fits with findings of previous research 
(Wilson, Ronnekleiv-Kelly, & Pawlik, 2017). A number of participants in the survey 
expressed their dissatisfaction with the way they were treated by their doctors through the 
open-text response option – some felt they did not have enough time to make a decision, were 
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not involved enough or were not given a choice of treatment but simply told what to do 
(Baunacke et al., 2020; Tenja, 2017). All of these findings suggest the importance of viewing 
the cancer patient as an individual who can and should be involved in their treatment decision 
if that is their preference. Their views, knowledge and feelings should be acknowledged 
regardless of their level of medical expertise. Patients and survivors are increasingly voicing 
their need to be more involved in the decisions surrounding their illness (Matsen, Lyons, 
Goodman, Biesecker, & Kaphingst, 2019), especially the decision concerning the treatment 
type which can impact individuals in many positive and negative ways.  
The relationship between the treatment-decision making process and the emergence of 
regret has been continuously highlighted in literature and the results mirror those of the 
current study. For example, a study of 804 prostate cancer patients found that a lack of 
discussion of all treatment options has been linked to higher levels of regret (Holmes et al., 
2017). Participants who underwent a discussion of all available treatment options with their 
healthcare professional were less likely to experience regret and this was confirmed by 
multivariate analysis controlling for a number of factors including age, race, marital status 
and education (Holmes et al., 2017). Again, this finding highlights the importance of 
involving the patient in their treatment decision and being open and transparent about their 
treatment options. It is understood that more regret is typically displayed by patients who feel 
their views are not taken into account, they experience little shared decision-making or their 
role in the decision-making is not matched with their preferred role (Wang et al., 2019; 
Wilding et al., 2020; Yamauchi, Nakao, & Nakashima, 2019). This was also evident in the 
findings of the current study.  
Regret has also been recently linked with unmet expectations and those expectations 
have been linked with a passive role in decision making and decisional conflict (Wollersheim 
et al., 2020).  A way to manage expectations again links to ensuring that patients are provided 
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with enough information (e.g. awareness of potential side effects). The current study found 
that information of side effects plays a role in the treatment decision making as 57.6 % 
participants reported that the possibility of side effects affected their decision. 
As discussed in Chapter 2, one way of ensuring the patient receives sufficient 
information and understands the consequences of their decision is the use of decision aids 
which, amongst other positive outcomes, lead to a decrease in decisional conflict and post-
treatment regret (Aning, Wassersug, & Goldenberg, 2012; Berlin et al., 2019; Søndergaard et 
al., 2019). This is a widely used intervention amongst healthcare professionals in oncology 
and other medical areas, which often proves very successful in allowing patients to make an 
informed treatment decision (Leinweber, Columbo, Kang, Trooboff, & Goodney, 2019).  
Poor literacy and numeracy, especially health literacy, affects regret levels post-treatment 
(Joyce et al., 2020), and decision aids may also be useful for those who receive low scores on 
these domains. However, more work in the area of decision aids for cancer patients is needed, 
especially in terms of the use of communicative aspects in the aids (Vromans et al., 2019). A 
systematic review of decision aids for prostate cancer patients revealed some issues found, 
like the lack of visual aids to communicate statistical information to patients who may not 
fully understand it, lack of interactive methods to highlight the preferences held by the 
patients, inclusion of biased tables to compare treatment or issues with suitability or 
accessibility to the decision  aids (Vromans et al., 2019). Another limitation of research in 
this area is the overall focus on prostate cancer decision making, with less emphasis on other 
cancers (Jones et al., 2018). This may be due to the many treatment options available for 
prostate cancer patients. However, patients of other cancers also face this type of decision. 
Too much time seeking information has been found to correlate with regret 
(Yamauchi et al., 2019), as well as seeking information from internet based sources 
(Shaverdian et al., 2018). Almost half of the participants in the current study (45.7%) 
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reported seeking information online. The correlation analysis found that those who reported 
spending more time seeking information online reported higher levels of regret, perhaps 
suggesting that searching for information online is not always helpful. While the internet can 
be a source of knowledge, it can also be a source of false, confusing or worrying information 
(Alsairi, Joury, Aljuaid, Wazzan, & Pines, 2017; Moolla, Adam, Perera, & Lawrentschuk, 
2019; Nghiem, Mahmoud, & Som, 2016). Feelings of receiving inadequate information, 
especially information of side-effects, have been linked with increased post-treatment regret 
(Albkri et al., 2018). Cancer survivors have also reported a need for guidance from healthcare 
professionals towards appropriate sources for guidelines on the importance of physical 
activity (Smith et al., 2017). Cancer patients should always be provided with sufficient 
information by their healthcare professionals, but also steered towards appropriate sources of 
knowledge in the form of information/support centres, appropriate websites, information 
booklets, information days, etc. 
Just like the findings in the systematic review contained in Chapter 2, these findings 
suggest that a lot of care needs to be taken by healthcare professionals not only to identify 
those who may be more at risk of experiencing regret, but also to mitigate the possibility of 
its emergence by selecting an appropriate treatment decision making procedure. An 
identification of the preferred involvement role may also be useful, as some patients do not 
want to be involved in the treatment decision making (Aminaie, Lehto, & Negarandeh, 2019). 
However, it should never be assumed that a patient does not want to be involved, and patient 
preferences should be considered. 
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5.6 The Role of Social Support in Cancer Survivorship 
The importance of social support in helping survivors cope is highlighted by the study 
results which suggest an association between lower levels of regret and higher levels of social 
support before, during and after treatment. Social support post treatment was also a 
statistically significant variable at step 2 of the regression analysis, further highlighting its 
potential importance. However, this association no longer appeared when accounting for 
other psychological factors in the regression analysis, suggesting that factors such as 
resilience and QOL are better predictors of regret. Family environment, having a close 
partner and a general support network have been continuously linked with better QoL and 
psychological wellbeing in cancer patients (Costa et al., 2017; Salakari et al., 2017; 
Thompson et al., 2017). Social support has also been linked with better physical wellbeing 
(Muscatell, Eisenberger, Dutcher, Cole, & Bower, 2016). However, social support must 
remain in place even after cancer-treatment in order to maintain emotional-wellbeing 
(Drageset, Lindstrøm, Giske, & Underlid, 2016; Fong, Scarapicchia, McDonough, Wrosch, & 
Sabiston, 2017). In the current study, satisfaction with social support was high before, during 
and after treatment. However, slightly less participants reported satisfaction with the social 
support received post treatment than before or during it. This may be due to the lack of 
understanding by members of society of the physical and emotional burden a cancer 
diagnosis leaves even after treatment and well into survivorship. The knowledge of 
importance of social support highlights the need of ensuring that support mechanisms are put 
in place for survivors. Information days for family members, partners or carers of those with 
cancer may be successful in creating an understanding of the need for support and ensuring 
that support systems remain in place even during survivorship. 
Perception of loneliness, which does not necessarily imply the lack of social support, 
was not measured in the current study, however an analysis of literature revealed its 
103 
importance as it has been shown to correlate with QoL, HRQoL and mental health in cancer 
patients (Hyland et al., 2019; Fanakidou et al., 2018). Loneliness not only affects the cancer 
patient, but also the caregiver who is at risk of a decrease in HRQoL if the patient they are 
caring for experiences a decrease in this domain (Segrin, Badger, & Sikorskii, 2019). 
Loneliness affects the patient-caregiver relationship (Segrin et al., 2019). This negative 
feeling can extend into survivorship, with survivors naming lack of control, feelings of being 
alone in their cancer experience, others’ avoidance and failure to recognise the effect of 
cancer post treatment as some of the factors related to loneliness (Raque-Bogdan, Lamphere, 
Kostiuk, Gissen, & Beranek, 2019). Other factors include social isolation, criticism from 
others related to the illness or questions about health status (Adams et al., 2016). Social 
support is one way of reducing loneliness and it may result in better mental health (Secinti et 
al., 2019). However, despite a large social support network, a cancer patient may feel lonely 
in the journey through illness, especially when feeling like those around them do not 
understand specific struggles (Adams et al., 2016). This is why support groups, both online 
and offline may play an important role in the lives of cancer survivors as they provide an 
outlet to meet others with similar experiences. Other factors that protect cancer patients from 
loneliness include maintaining a normal routine or thoughts and beliefs that time alone may 
be desirable and that it is normal for others (who are not ill) to feel discomfort around 
discussions of cancer (Adams et al., 2016). 
 While the importance of support for cancer survivors both online and offline is 
increasingly recognised, an interesting result was found in the current study in those who 
used both types of support groups. While the majority of participants did not use either, 
30.4% availed of online support and 43.5% availed of face-to-face support at some stage of 
the survivorship trajectory. The participants who used either/both support service types 
experienced higher levels of regret compared with the survivors who did not use any support 
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services. Despite the number of regretful participants in the current study being low, this 
finding may suggest that those who experience regret are more likely to seek support 
services. This contrasts with the finding that psychological distress does not necessarily equal 
higher use of support services amongst cancer patients and survivors (Matsui & Tanimukai, 
2017). If the findings in the current study suggests that support services are not successful in 
mitigating decisional regret, they also contrast studies which find that both online and face-
to-face support services allow cancer patients to cope better with their illness (Gottlieb & 
Wachala, 2007; Høybye, Johansen, & Tjørnhøj‐Thomsen, 2005; Klemm, 2003). Cancer 
patients and survivors often praise the support services used (Villarreal-Garza et al., 2020).
 The qualitative analysis in the current study revealed that some participants felt 
dissatisfaction at the lack of psychological support available to them at the time of their 
illness while others attributed their wellbeing to the support received. Cancer patients and 
survivors should always be notified of various support services available and that the services 
will cater for their specific needs. The Irish Cancer Society official website lists 38 support 
groups which can be found nationwide, 3 of which are aimed at children and adolescents. The 
support groups provide extremely valuable face-to-face help to cancer patients and survivors 
but online supports, especially in the form of Facebook groups and Internet forums are 
growing in popularity due to the ease of sharing and receiving information and are especially 
helpful for younger users (Huber, Maatouk, & Ihrig, 2018). The anonymity provided by 
online services may be perceived as an advantage, as cancer patients and survivors may feel 
more comfortable sharing their stories and asking questions without being known. However, 
many individuals attend support groups for the social aspect, as face-to-face contact is 
important for psychological wellbeing, especially for older cancer survivors (Huber et al., 
2018).  
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Many of the traditional support groups were forced to move their services online or to 
provide support over-the-phone in-light of the Covid-19 pandemic. Their services did not 
stop during this time, given their perceived essential nature. It is likely that the Covid-19 
pandemic has increased engagement and provision of online supports which hopefully will be 
sustained in the future. However, it is not yet known whether these online supports will have 
similar benefits to survivors as offline supports and more research is needed in this area. 
5.7 Psychological Appraisals in Regret 
In addition to social support, the analysis suggests that positive psychological 
appraisals may play a role in the emergence of regret, with survivors displaying higher levels 
of optimism, autonomy, purpose and resilience experiencing less regret. As contemporary 
research now aims to focus on more than just the negative aspects of illness and survivorship, 
more evidence suggesting the importance of positive psychological appraisals for higher QoL 
has emerged (Chamber et al., 2012; Ristevska-Dimitrovska, Filov, Rajchanovska, 
Stefanovski, & Dejanova, 2015). However, out of all of the positive psychological variables 
tested in the current study, only resilience remained statistically significant in the final 
regression model. This result mirrors literature findings which suggest the important role 
resilience has in higher levels of psychological wellbeing in cancer patients (Costa et al., 
2017; Lai, Hung, Chen, Shih, & Huang, 2020; Li, Yang, Liu, Wang, 2016). Resilience is also 
known to predict QOL/wellbeing in those with chronic illness. A study which analysed 
factors associated with wellbeing in those with illness found that resilience was more 
important in the wellbeing of those limited by health than those who were not (Maguire, 
Hanly, & Maguire, 2019), which suggests that this may be particularly important in those 
more severely impacted by cancer. 
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Resilience has been described as a set of baseline personal characteristics or traits 
which equip an individual to cope with adverse experiences and protect against psychological 
distress (Molina et al., 2014). Resilience is influenced by characteristics such as 
sociodemographic factors and personal resources like hope or optimism (Molina et al., 2014). 
Rather than being viewed as a stable trait, resilience is considered to be a dynamic process 
which can developed in cancer patients (Chmitorz et al., 2018). Despite its known importance 
by researchers and healthcare professionals, a systematic review of 32 qualitative studies 
found that no cancer patients used the word resilience when discussing their coping strategies 
(Tan, Beatty, & Koczwara, 2019). Instead words like hope or social support were used (Tan 
et al., 2019). This may suggest a lack of awareness of what resilience is and a call for 
increased attempts at educating patients and survivors on ways to build it.  
These findings suggest the potentially important role that positive psychological 
appraisals may play in reducing the likelihood of regret and could encourage future research 
to focus on finding ways to foster resilience in cancer patients (Booth et al., 2020; Rosenberg 
et al., 2018; Solano, de Silva, Soares, Ashmawi, & Vieria, 2016). Some research has begun in 
this area and higher levels of resilience have been found in patients who are physically more 
active (Matzka et al., 2016). Biological, personal and social factors also contribute to 
resilience in cancer patients and it can be modified through psychological and 
pharmacological interventions (Seiler & Jenewein, 2019). Resilience can also be influenced 
by a range of factors, examples of which include: perceived social support, less hopelessness 
(Somasundaram & Devamani, 2016), spirituality (Hunter-Hernández, Costas-Muñíz, & 
Gany, 2015), higher education level (Wu, Liu, Li, & Li, 2016), older age or male gender 
(Cohen, Baziliansky, & Beny, 2014).  
Studies describe many interventions aimed at fostering resilience in cancer patients 
but also in other populations. Some examples of interventions used are: online interventions 
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which teach basic skills to improve resilience, persistence and ability to cope (Abbott, Klein, 
Hamilton, & Rosenthal, 2009; Bekki, Smith, Bernstein, & Harrison, 2013), the READY 
programme which aims to improve positive emotions, cognitive flexibility, social support, 
life meaning, and active coping (Burton, Pakenham, & Brown, 2009) or the SMART 
programme which teaches self-care (relaxation techniques, positive thoughts, healthy eating, 
physical exercise) and helps participants understand the relationship between stress and 
physical and emotional problems (Loprinzi, Prasad, Schroeder, & Sood, 2011). However, 
some interventions have not been found to be successful, for example, a stress management 
programme and a therapeutic music video-intervention for young adults with cancer (Greup 
et al., 2018). A systematic review of resilience fostering techniques which occurred between 
1979 and 2014 found that their efficacy is difficult to assess due to problems with the 
concepts, methods, designs and definitions of resilience used (Chmitorz et al., 2018). This 
warrants more research in the area of fostering resilience. 
5.8 Limitations and Strengths 
One of the limitations of the current study is the small sample size. The participant 
recruitment process proved difficult and it was not possible to find as many participants as 
intended, meaning that the analysis was under-powered. Females were also over-represented 
in the analysis. The cross-sectional nature of the study is another limitation. The data 
collected refers to only one time-point in the participants’ cancer survivorship. The study may 
have provided more useful insights into life post-cancer treatment in Ireland if it was of 
longitudinal nature. A potential limitation was the failure to adequately control for Type 1 
errors in the analysis. Given the large amount of variables investigated, it is possible that 
false positive results could have occurred. Lastly, the regression analysis was slightly 
underpowered and this is also a limitation of the current study. 
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Despite the small sample size, the participants included in the study reported an array 
of cancer types, cancer treatments availed of as well as experiences associated with their 
illness. The study does provide an interesting insight into life post cancer-treatment in 
Ireland, describes the characteristics of a sample of Irish cancer survivors who have 
undergone treatment, explores the experiences of decision making in relation to cancer 
treatment and the associations between sociodemographic, health, decision making, and 
social factors and their relationship with decisional regret. The results of the study provide an 
insight into the feelings of regret various cancer survivors hold between 1 and 22 years post 
treatment. The collection of qualitative comments also gives a more personal insight in the 
experiences of the participants, suggesting the range of positive and negative experiences 
encountered. 
5.9 Conclusion 
The current study highlights the factors associated with regret in cancer survivors in 
Ireland. Results suggest who may be more at risk of experiencing regret and build on the 
findings of study 1 (i.e., systematic review). This knowledge may aid future developments of 
ways to identify patients most at risk of developing feelings of regret post-treatment. These 
issues are expanded upon in the final chapter. 
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Chapter 6 
Conclusion 
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6.1 Overview 
The current research aimed to explore the factors which have been found to be 
associated with the emergence of decisional regret in cancer patients and survivors. This was 
achieved by two studies. Study 1 was an inclusive systematic review of international 
literature and Study 2 was a survey of cancer survivors living in Ireland. From the 
comparison of the results from Study 1 and Study 2, it can be concluded that cancer patients 
and survivors have similar needs in Ireland and internationally. Similar factors associated 
with post-treatment regret emerged both in the systematic review and the cross-sectional 
survey. This chapter will briefly review these similarities and state how these findings can aid 
future interventions aimed at improving the wellbeing of oncology populations. This chapter 
also includes a PPI (Public and Patient Involvement) section, as the results of the two studies 
were presented to a number of Irish cancer survivors to allow for a more meaningful 
interpretation of the study findings. 
6.2 Public and Patient Involvement Results 
The value of public and patient involvement in the design, conduct and dissemination 
of research is widely recognised and even required by many funding bodies. PPI has been 
shown to improve the meeting of participation targets in research studies (Ennis & Wykes, 
2013) and clinical trials (Crocker et al., 2018). In the current project, PPI was used in order to 
receive cancer survivor feedback on research results.  
Nine responses were collected from four males and five females. Just like the results 
of both of the studies in the current project, the feedback provided varied according to 
individual experiences. Some cancer survivors related to the findings, while others did not. A 
strong trend emerging from the feedback was the overall positive comments the survivors 
shared about their own experience and how it differed from the regretful experiences 
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described in the study results. The survivors commented about being happy with their 
treatment, being involved in shared decision making which was described as “good” and 
reported having no regrets. One female cancer survivor went as far as stating that people 
should not regret anything about their cancer experience because “there is a better survivor 
rate nowadays”, “there is lots of support out there through your family, friends, work mates 
and many cancer support groups” and “it (treatment) gives you life back”. A male cancer 
survivor stated that he relates to the findings of Study 2, stating: “I have a good quality of 
life, I shared the decision process and I am very resilient. Had I not had the above 3 positive 
outlooks I imagine I would have not coped as well”. These positive comments about the 
individuals’ own experiences are welcomed as they imply that cancer survivorship can be a 
hopeful time. They also reinforce the knowledge that generally, decisional-regret in cancer 
patients is low. 
However, some regret, fear of recurrence and worry was evident amongst a number of 
individuals providing PPI feedback. One male survivor commented on the never-ending 
battle between cherishing the win against cancer and worrying that it will come back again: 
“Being a survivor is great but any pain or abnormality I notice I always have the fear of my 
cancer coming back, this never goes away”. The same individual stated that he relates to the 
study findings due to his own financial difficulties during treatment: “Yes especially the part 
about financial difficulty because I worried I would not be able to afford my treatments and 
medications”. A female survivor commented on her regret associated with the side effects of 
the cancer and chemotherapy and her wish to have been more informed at the time. Similarly, 
a male cancer survivor stated that while he made the correct decision by removing his 
prostate soon post-diagnosis, the long-term effect of losing sexual function at a young age 
was very difficult. Again, these comments reinforce the study findings and show that 
negative thoughts, feelings and experiences can be carried from the illness to survivorship. 
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While the current project did not find any patterns between regret and age, one female 
cancer survivor felt strongly about the differences in coping strategies between younger and 
older cancer patients. The individual stated that she was 63 when diagnosed with cancer and 
that she felt that it was easier than if it happened if she was younger. She also stated that 
“women who are young need a lot more help and counselling”. This is an interesting insight 
as it shows how much socio-demographic factors and individual circumstances can impact 
cancer experiences. 
All of the survivors agreed that the findings of the current research are valuable and 
important in the continuous journey towards better support for cancer survivors post-
treatment. When asked to provide their opinions on the findings of the project, the individuals 
provided the following answers: “It seems like a really well done project with important 
findings which can help some people.”, “It is great to see research being conducted on this 
topic. I wish more people were concerned with the psychological well-being of cancer 
survivors.”, “As a cancer survivor I am happy to see these findings.”, “I feel that a 
questionnaire like this should be available to all cancer survivors.”. 
6.3 Implications 
 The results of both the systematic review and the survey revealed that the experience 
of regret is typically low in cancer survivors. While this is a positive finding, it is clear that 
some survivors are more at risk than others. Results of the two studies presented indicate that 
factors associated with regret in cancer patients and survivors both in Ireland and 
internationally can be divided into five categories: sociodemographic factors, factors 
associated with health/physical wellbeing, factors related to the treatment type underwent, 
factors associated with the decision making process, and psychosocial factors. The findings 
of the project suggest that regret often does not occur as a result of or in association with one 
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factor only, suggesting that this is a complex process. The implications of the current findings 
suggest that each cancer patient should be viewed as an individual who brings their own 
experiences, knowledge and feelings into the treatment decision making process as post-
treatment regret and reduced quality of life can occur for various reasons. The findings also 
highlight the need for continuous care for cancer survivors, as the negative effects of cancer 
and its treatment can reduce wellbeing even during survivorship. Lastly, the findings of both 
studies may allow healthcare providers, carers or support service workers an easier 
identification of individuals most likely to experience treatment regret. As discussed in the 
previous chapter, this knowledge may alter the care and support provided according to 
individual needs. 
 A well-established concept of care for individuals transitioning from being a cancer 
patient to being a cancer survivor is Person Centered Care which puts the individual’s needs, 
values and preferences first (Loonen et al., 2018). This component of care responds to the 
need to view each survivor as an individual with personal experiences as well as the need to 
continue the provision of care during survivorship. According to its three main components, 
person centred care initiates, intergrades and safeguards the relationship between the 
healthcare provider and the survivor (Loonen et al., 2018). Initiation places the survivor’s 
perspective of their life experiences and health condition at the centre of care (Loonen et al., 
2018). Integration allows for sharing information between the healthcare provider and the 
survivor with respect to the survivor’s narrative and understanding of the survivor’s 
preferences regarding their care (Loonen et al., 2018). Safeguarding protects the partnership 
between the healthcare provider and the survivor through the registration of information on 
the survivor’s care preferences and health concerns (Loonen et al., 2018). Person centred care 
has been shown to be a successful agent in creating better physical and psychological 
outcomes for survivors (Olesen et al., 2016; Temple-Oberle et al., 2014). The results of the 
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two studies presented in the current thesis suggest: the need for respect to be given to cancer 
patients and survivors, for more choice and involvement of patients in treatment decision 
making, for continuous access to support for individuals and for the provision of accurate, 
relevant and comprehensive information by healthcare providers – patient centred care 
ensures all of these needs are met (Groves, 2010). 
6.3.1 Conceptual implications  
Apart from highlighting the importance of viewing cancer survivors as individuals 
who may need ongoing support long after completing their treatment, the results of the 
current research advance a number of aspects of psychological theory including theories of 
decisional regret (e.g., Decision Justification Theory; Connolly & Zeelenber, 2002), decision 
making (Theory of Risk Aversion; Breen et al., 2014) and positive psychology.  
Existing theories of decisional regret attempt to explain what decisional regret is as 
well as suggesting reasons for its occurrence and ways that it occurs. The current research 
advances our knowledge of regret in cancer patients and suggests that the reasons for its 
occurrence are complex and rarely occur in isolation. The current research also highlights the 
longevity of this phenomenon, as cancer survivors in both studies displayed decisional regret 
at time points ranging from a few months to many years post-treatment. Lastly, the current 
study highlights the importance on interventions which can mitigate the occurrence of 
decisional regret in patients and survivors.  
The current research also advances theories of decision making by showing that the 
process in which a decision is made can be as important as the actual decision itself in 
determining the feelings a person later experiences towards their choice. Shared decision 
making is presented in both studies as a desirable way of making health-related decisions as it 
has repeatedly been linked with lower levels of treatment-related regret. 
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Finally, the current study advances knowledge of the importance of positive 
psychology by highlighting the value of fostering optimism, autonomy, purpose and 
resilience in survivors. In recent literature, resilience is often mentioned as essential for 
psychological wellbeing and good quality of life. The current research highlights its 
importance in an oncology setting. In both studies, resilience was linked with lower levels of 
regret. The need for resilience building interventions has also been highlighted.  
To conclude, cancer survivors and their needs must not be overlooked by healthcare 
professionals, support service providers or close family and friends due to their success in 
beating the illness. Studies have shown that survivorship can cause as many physical and 
psychological struggles as the illness, and that cancer survivors should continue to receive 
appropriate supports which can improve their QoL. The findings of this project highlight gaps 
in knowledge as well as gaps in supports available, particularly in Ireland. 
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154 
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Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.   
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Risk of bias in individual 
studies   
12  Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.   
 24 
Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).    24 
Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.   
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Risk of bias across studies   15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).   
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Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.   
 N/A 
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Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.   
 23 
Study characteristics   18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.   
 27 
Risk of bias within studies   19  Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).    N/A 
Results of individual studies   20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.   
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Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of consistency.   N/A  
Risk of bias across studies   22  Present results of any assessment of risk of bias across studies (see Item 15).    N/A 
Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).    N/A 
DISCUSSION       
Summary of evidence   24  Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).   
 38-45 
Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).   
55 
Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and implications for future research.   49-55 
FUNDING       
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Appendix B: Mixed Methods Appraisal Tool 
 
Category of study 
designs 
Methodological quality criteria Yes  No Can’t 
tell 
Comments 
Screening 
questions (for all 
types) 
S1. Are there clear research questions?     
S2. Do the collected data allow to address the research questions?     
1. Qualitative 1.1. Is the qualitative approach appropriate to answer the research question?     
1.2. Are the qualitative data collection methods adequate to address the research question?     
1.3. Are the findings adequately derived from the data?     
1.4. Is the interpretation of results sufficiently substantiated by data?     
1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation?     
2. Quantitative 
randomized 
controlled trials 
2.1. Is randomization appropriately performed?     
2.2. Are the groups comparable at baseline?     
2.3. Are there complete outcome data?     
2.4. Are outcome assessors blinded to the intervention provided?     
2.5 Did the participants adhere to the assigned intervention?     
3. Quantitative 
nonrandomized 
3.1. Are the participants representative of the target population?     
3.2. Are measurements appropriate regarding both the outcome and intervention (or exposure)?     
3.3. Are there complete outcome data?     
3.4. Are the confounders accounted for in the design and analysis?     
3.5. During the study period, is the intervention administered (or exposure occurred) as intended?     
4. Quantitative 
descriptive 
4.1. Is the sampling strategy relevant to address the research question?     
4.2. Is the sample representative of the target population?     
4.3. Are the measurements appropriate?     
4.4. Is the risk of nonresponse bias low?     
4.5. Is the statistical analysis appropriate to answer the research question?     
5. Mixed 
methods 
5.1. Is there an adequate rationale for using a mixed methods design to address the research question?     
5.2. Are the different components of the study effectively integrated to answer the research question?     
5.3. Are the outputs of the integration of qualitative and quantitative components adequately interpreted?     
5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed?     
5.5. Do the different components of the study adhere to the quality criteria of each tradition of the methods involved?     
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Appendix D: Survey  
SECTION A: ABOUT YOU  
Please answer all the following questions by ticking the appropriate box or using the space 
provided. 
 
A1. What is your age?             
 ________________________________________ 
 
A2. How would you describe your gender? 
Male    ☐   Female   ☐ 
I’m not sure/questioning ☐   Prefer not to say  ☐ 
Other (e.g. non-binary), please specify __________________a 
 
A3. What is your nationality?           
Irish ☐ Other  ☐ 
If other, please describe ________________________    
 
A4. Do you have dependent children? 
Yes  ☐   No  ☐ 
 
A5. What is your marital status? Please tick one box  
Married   ☐  Separated    ☐ 
Never Married   ☐  Divorced    ☐ 
Widowed   ☐  Living with partner/co-habiting ☐ 
Living in a civil partnership ☐ 
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A6. What is the highest level of education you completed? Please tick one box     
Primary school ☐  Third level (e.g., college, university)      ☐ 
Secondary school ☐  Postgraduate (e.g., masters, doctorate)             ☐ 
 
A7. Which of the following best describes you? 
Working for an employer      ☐ 
Looking after family/home       ☐ 
Unable to work due to permanent sickness/disability   ☐ 
Self-employed        ☐ 
Retired        ☐ 
Student        ☐ 
Unemployed        ☐ 
If other, please specify ___________________________________ 
 
A8. Has your employment status changed since your diagnosis? 
Yes  ☐   No  ☐ 
 
A9. Do you provide regular unpaid personal help for a family member with a long-term 
illness, health problem or disability? (Includes problems due to old age. Personal help 
includes help with basic tasks such as feeding or dressing). 
Yes  ☐   No  ☐ 
 
A10. Thinking of your total monthly income: are you able to make ends meet..? 
Very easily Easily Fairly easily With some 
difficulty 
With 
difficulty 
With great 
difficulty 
      
  
A11. How long ago were you diagnosed with cancer? 
____________________________________ 
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A12. What type of cancer were you diagnosed with? 
____________________________________ 
 
A13. Apart from being diagnosed with cancer, have you got any other chronic health 
conditions you wish to mention? (If yes, please specify) 
_________________________________ 
 
SECTION B: TREATMENT DECISION MAKING  
Please answer all the following questions by ticking the appropriate box or using the space 
provided. 
 
B1. Please describe the PRIMARY treatment you underwent following your diagnosis 
(e.g., surgery, medication, radiotherapy, chemotherapy, etc.) 
____________________________________________________________________ 
B2. How long ago did you undertake the primary treatment? 
____________ years ____________ months 
 
B3. Is the treatment currently ongoing? 
Yes ☐  No  ☐ 
 
B4. Was there more than one treatment option available to you? 
Yes  ☐  No ☐  Unsure  ☐ 
If yes, how many treatment options were available to you? ____________ 
 
B5. Apart from your doctor, is there anybody else you spoke to about your treatment 
options? (e.g., family, friends, partner, children, colleague, etc.) 
Yes ☐  No ☐ 
If Yes, please describe who you spoke to______________ 
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B6. a. Did you feel you had enough time to make a decision about your treatment?  
Yes ☐  No ☐ 
 
b. Who were the people who most influenced your decision regarding your treatment? 
Rank in terms of importance. 
1.____________________________ 
2.____________________________ 
3.____________________________ 
 
B7. Did you seek a second medical opinion prior to making a treatment decision with 
your doctor? 
Yes  ☐  No ☐ 
 
B8. Did the possibility of side effects affect your treatment decision? 
Yes, strongly ☐   Yes, slightly ☐   No, not at all ☐ 
 
B9. a. Did you seek any information about your treatment options online? 
Yes ☐  No ☐ 
 
b. If yes, how would you rate the amount of time you spent conducting online research 
about your treatment options? Please circle the appropriate number. 
1  2  3  4  5  6  7 
I spent very little               I spent a lot of 
time researching           time researching 
my treatment                   my treatment 
options online                options online 
 
 
 
 
173 
B10. How well informed did you feel at the time of your decision? 
1  2  3  4  5  6  7 
Not at all          Extremely 
well informed               well informed 
 
B11. How well informed do you feel now about the treatment you received? 
1  2  3  4  5  6  7 
Not at all          Extremely 
well informed               well informed 
 
B12. Nine statements related to the decision-making in your consultation are listed 
below. For each statement please indicate how much you agree or disagree by ticking 
the box beside the statement that applies to you.         
 Completely 
disagree 
Strongly 
disagree 
Somewhat 
disagree 
Somewhat 
agree 
Strongly 
agree 
Completely 
agree     
a. My doctor 
made clear that a 
decision needed to 
be made. 
      
b. My doctor 
wanted to know 
exactly how I 
wanted to be 
involved in 
making the 
decision. 
      
c. My doctor told 
me that there 
were different 
options for 
treating my 
medical 
condition. 
      
d. My doctor 
precisely 
explained the 
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advantages and 
disadvantages of 
the treatment 
options. 
e. My doctor 
helped me 
understand all the 
information. 
      
f. My doctor 
asked me which 
treatment option 
I preferred. 
      
g. My doctor and 
I thoroughly 
weighed the 
different 
treatment 
options. 
      
h. My doctor and 
I selected a 
treatment option 
together. 
      
i. My doctor and I 
reached an 
agreement on 
how to proceed. 
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SECTION C: How you feel about your choice  
Please think about the decision you made about your treatment after talking to your health 
professional. Please show how you feel about these statements by ticking the box beside the 
statement which most applies to you. 
 
 Strongly 
agree  
Agree Neither 
Agree or 
Disagree 
Disagree Strongly 
Disagree 
C1. It was the right decision      
C2. I regret the choice that I made      
C3. I would go for the same choice 
if I had to do it over again 
     
C4. The choice did me a lot of 
harm 
     
C5. The decision was a wise one      
 
Section D: HOW YOU FEEL SINCE YOUR TREATMENT  
For the following two questions please circle the number between 1 and 7 that best applies to 
you  
 
D1. How would you rate your overall physical condition during the past month?   
1  2  3  4  5  6  7                               
Very Poor                                            Excellent  
 
D2. How would you rate your overall quality of life during the past month?  
1  2  3  4  5  6  7                                  
Very Poor                                       Excellent 
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D3. Under each heading below, please tick the ONE box that best describe your own 
health TODAY   
a. Mobility 
I have no problems in walking about    ☐ 
I have slight problems in walking about   ☐             
I have moderate problems in walking about   ☐                  
I have severe problems in walking about   ☐         
I am unable to walk about     ☐              
        
b. Self-care  
I have no problems washing or dressing myself  ☐                             
I have slight problems washing or dressing myself  ☐                            
I have moderate problems washing or dressing myself      ☐                           
I have severe problems washing or dressing myself  ☐                               
I am unable to wash or dress myself                ☐                  
     
c. Usual Activities (e.g. Work, study, housework, family or leisure activities)             
I have no problems doing my usual activities  ☐              
I have slight problems doing my usual activities  ☐                 
I have moderate problems doing my usual activities  ☐                                        
I have severe problems doing my usual activities  ☐                                 
I am unable to do my usual activities    ☐                  
 
d. Pain/Discomfort  
I have no pain or discomfort     ☐                                
I have slight pain or discomfort    ☐                                 
I have moderate pain or discomfort    ☐                                
I have severe pain or discomfort    ☐                                 
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I have extreme pain or discomfort    ☐                 
        
e. Anxiety/Depression  
I am not anxious or depressed    ☐                                 
I am slightly anxious or depressed    ☐                                
I am moderately anxious or depressed   ☐                                
I am severely anxious or depressed    ☐                                 
I am extremely anxious or depressed    ☐            
          
SECTION E: SOCIAL SUPPORT  
The following questions are about the support you received from the people in your life. 
Please answer the question by ticking the box under the statement that applies to you. 
 
E1. While making the decision about my treatment, I was satisfied with the support I 
had from other people in my life (e.g., family, friends, neighbours, etc.) 
1. Strongly 
agree 
2. Moderately 
agree 
3. Slightly 
agree 
4. Slightly 
disagree 
5. Moderately 
disagree 
6. 
Strongly 
disagree 
      
 
E2. During my treatment, I was satisfied with the support I had from other people in 
my life (e.g., family, friends, neighbours, etc.) 
1. Strongly 
agree 
2. Moderately 
agree 
3. Slightly 
agree 
4. Slightly 
disagree 
5. Moderately 
disagree 
6. 
Strongly 
disagree 
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E3. Currently, I am satisfied with the support I had from other people in my life (e.g., 
family, friends, neighbours, etc.) 
1. Strongly 
agree 
2. Moderately 
agree 
3. Slightly 
agree 
4. Slightly 
disagree 
5. Moderately 
disagree 
6. 
Strongly 
disagree 
      
 
SECTION F: SUPPORT SERVICES  
Please answer the questions in this section by ticking the box beside the statement that 
applies to you. 
 
F1. Have you used any online support services since your diagnosis? 
Yes  ☐  No   ☐ 
If yes, what online support service did you use?  _______________ 
If yes, when did you use it?    Before treatment ☐ 
       During Treatment ☐ 
       After Treatment ☐ 
If yes, do you feel the online support service provided you with the help you needed? 
Yes  ☐  No   ☐ 
 
F2. Have you used any other support services since your diagnosis? E.g., information 
days held in hospitals, cancer “buddy” scheme, a cancer support centre, a cancer 
support group, etc.  
Yes  ☐  No ☐ 
If yes, what support service did you use?     _______________ 
If yes, when did you use it?    Before treatment ☐ 
       During Treatment ☐ 
       After Treatment ☐ 
If yes, do you feel the support service provided you with the help you needed? 
Yes  ☐  No   ☐ 
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SECTION G: FINALLY 
 
G1. Please answer the question by ticking the box beside the statement that applies to 
you. 
 Strongly 
agree  
Agree Neither agree 
nor disagree 
Disagree Strongly 
disagree 
G1. I am optimistic about 
my future 
     
G2. I generally feel that 
what I do in life is 
worthwhile. 
     
G3. I feel I am free to 
decide how to live my life. 
     
 
 
G4. I find it difficult to 
deal with important 
problems that come up in 
my life. 
     
G5. When things go wrong 
in my life, it generally 
takes me a long time to get 
back to normal. 
     
 
G2. Is there anything else you would like to add? 
 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
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Thank you for your participation! If you are satisfied with the information you 
provided and wish to submit it, please return the survey to the researcher.  
If you experience any distress following the questionnaire, you may contact the Irish 
Cancer Society (Cancer Nurseline: Freephone 1800 200 700 (Monday-Friday 9-5), Cancer 
Information Enquiries: cancernurseline@irishcancer.ie, online: www.cancer.ie). You may 
also contact my supervisor, Dr. Rebecca Maguire (rebecca.maguire@mu.ie), if you feel the 
research has not been carried out as described previously. 
Any further queries?  If you need any further information, you can contact me: 
Aleksandra Szproch, aleksandra.szproch.2016@mumail.ie 
If during your participation in this study you feel the information and guidelines that 
you were given have been neglected or disregarded in any way, or if you are unhappy about 
the process, please contact the Secretary of the Maynooth University Ethics Committee at 
research.ethics@mu.ie or +353 (0)1 708 6019. Please be assured that your concerns will be 
dealt with in a sensitive manner. 
For your information the Data Controller for this research project is Maynooth 
University, Maynooth, Co. Kildare. Maynooth University Data Protection officer is Ann 
McKeon in Humanity house, room 17, who can be contacted at ann.mckeon@mu.ie. 
Maynooth University Data Privacy policies can be found at 
https://www.maynoothuniversity.ie/data-protection. 
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Appendix E: Maynooth University Research Ethic Committee Ethical Approval 
 
MAYNOOTH UNIVERSITY RESEARCH ETHICS COMMITTEE    
MAYNOOTH UNIVERSITY,  
MAYNOOTH, CO. KILDARE, IRELAND  
  
  
Dr Carol Barrett   
Secretary to Maynooth University Research Ethics Committee  
  
14 December 2018  
  
Aleksandra Szproch  
Department of Psychology  
Maynooth University  
  
RE: Application for Ethical Approval for a project entitled: Exploring reflections of 
health-related decision making following treatment  
  
Dear Aleksandra,  
  
The Ethics Committee evaluated the above project and we would like to inform you that 
ethical approval has been granted.  
  
Any deviations from the project details submitted to the ethics committee will require further 
evaluation.  This ethical approval will expire on 31 December 2019.  
  
  
Kind Regards,  
  
Dr Carol Barrett  
Secretary,   
Maynooth University Research Ethics Committee  
  
C.c.Dr Rebecca Maguire, Department of Psychology, Maynooth University  
Reference Number  SRESC-2018-139  
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Appendix F: Information Sheet 
 
Purpose of the Study.  I am Aleksandra Szproch, an MSc student, in the Psychology 
Department at Maynooth University.  
 
As part of the requirements for an MSc degree, I am undertaking a research study under the 
supervision of Dr. Rebecca Maguire.  
 
The study is concerned with the experience cancer survivors had while deciding about their 
treatment, how they feel about their decision now and how they are feeling since undertaking 
their chosen treatment. 
 
What are the advantages of taking part? The research has potential to inform interventions 
aimed at helping cancer patients make the best decisions regarding their treatment. The current 
research has the potential to benefit many cancer-patients in the future. The information found 
has the potential to help ensure that cancer-patients receive the best possible help while being 
faced with a treatment decision. This can minimise the emergence of decisional regret and stop 
the decrease of the quality of life and well-being of cancer patients/survivors post-treatment. 
 
What are the possible disadvantages of taking part? If you had a negative experience during 
your consultation with your doctor, during the treatment decision making process or 
during/after your treatment, it is possible that talking about your experience may cause some 
distress. This questionnaire will ask you to think about those times and to answer questions 
accordingly.  
 
What if there is a problem? If you experience any distress following the questionnaire, you 
may contact the Irish Cancer Society (Cancer Nurseline: Freephone 1800 200 700 (Monday-
Friday 9-5), Cancer Information Enquiries: cancernurseline@irishcancer.ie, online: 
www.cancer.ie). You may also contact my supervisor, Dr. Rebecca Maguire (Email: 
rebecca.maguire@mu.ie, Phone: +353 1 4747624), if you feel the research has not been carried 
out as described above. 
 
What will the study involve? The study will involve a questionnaire which will take approx. 
15-30 minutes to complete. 
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Who has approved this study?  This study has been reviewed and received ethical approval 
from Maynooth University Research Ethics committee. You may have a copy of this approval 
if you request it.  
 
Why have you been asked to take part? You have been asked because you are a cancer 
survivor who has made a decision about their cancer treatment. 
  
Do you have to take part? No, you are under no obligation whatsoever to take part in this 
research. However, we hope that you will agree to take part and give us some of your time to 
complete this short questionnaire. It is entirely up to you to decide whether or not you would 
like to take part. If you decide to do so, you will be asked to read an information sheet and 
complete a consent form. If you decide to take part, you are still free to withdraw at any time 
without giving a reason.  
 
What information will be collected? Demographic information, information about your 
diagnosis, information about your treatment decision making process, information about how 
you felt about your treatment decision, information about the social support you received 
before, during and since treatment, information about support groups which you have been or 
are currently part of, information about your physical/psychological/social well-being since 
your treatment. 
 
Will your participation in the study be kept confidential? Yes, all information that is 
collected about you during the course of the research will be kept confidential. No names will 
be identified at any time. All hard copy information will be held in a locked cabinet at the 
researchers’ place of work, electronic information will be encrypted and held securely on MU 
PC or servers and will be accessed only by the researcher (Aleksandra Szproch). 
 
No information will be distributed to any other unauthorised individual or third party. As no 
personal identifiable information will be collected, you will not be able to seek your data after 
the submission of the completed questionnaire. 
 
‘It must be recognised that, in some circumstances, confidentiality of research data and 
records may be overridden by courts in the event of litigation or in the course of investigation 
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by lawful authority. In such circumstances the University will take all reasonable steps within 
law to ensure that confidentiality is maintained to the greatest possible extent.’  
 
What will happen to the information which you give? All the information you provide will 
be kept at Maynooth University in such a way that it will not be possible to identify you. On 
completion of the research, the data will be retained on the MU server. After ten years, all 
data will be destroyed (by the PI). Manual data will be shredded confidentially and electronic 
data will be reformatted or overwritten by the PI in Maynooth University. 
 
What will happen to the results? The research will be written up and presented as a thesis. 
It may be discussed at internal group meetings, presented at National and International 
conferences and may be published in scientific journals. A copy of the research findings will 
be made available to you upon request. 
 
Any further queries?  If you need any further information, you can contact me: Aleksandra 
Szproch, aleksandra.szproch.2016@mumail.ie 
 
Consent: If you wish to take part, you can simply click on the arrow below and complete the 
consent form. You may then complete the survey.   
 
Thank you for taking the time to read this 
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Appendix G: Consent Form  
 
Please tick each statement below: 
 
The purpose and nature of the study has been explained to me in writing.    ☐ 
 
I am participating voluntarily.          ☐ 
 
I understand that I can withdraw from the study, without repercussions, at any time, whether that is before it 
starts or while I am participating.          ☐ 
 
It has been explained to me how my data will be managed.      ☐ 
 
I understand the limits of confidentiality as described in the information sheet.   ☐ 
 
I understand that my data, in an anonymous format, may be used in further research projects and any 
subsequent publications if I give permission below:         ☐ 
 
I agree for my data to be used for further research projects      ☐ 
I do not agree for my data to be used for further research projects     ☐ 
 
I confirm that I am over 18 years old         ☐ 
 
I confirm that English is my first language        ☐ 
     
I confirm that I am at least one year post-cancer diagnosis      ☐ 
 
I confirm that I have selected and undergone cancer treatment      ☐ 
 
I confirm that currently I am not a cancer patient        ☐ 
 
Do you agree to take part in Aleksandra Szproch’s study?   Yes  ☐  No  ☐ 
 
If during your participation in this study you feel the information and guidelines that you were given have 
been neglected or disregarded in any way, or if you are unhappy about the process, please contact the 
Secretary of the Maynooth University Ethics Committee at research.ethics@mu.ie or +353 (0)1 708 6019. 
Please be assured that your concerns will be dealt with in a sensitive manner. 
 
For your information the Data Controller for this research project is Maynooth University, Maynooth, Co. 
Kildare. Maynooth University Data Protection officer is Ann McKeon in Humanity house, room 17, who can 
be contacted at ann.mckeon@mu.ie. Maynooth University Data Privacy policies can be found at 
https://www.maynoothuniversity.ie/data-protection. 
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Appendix H: Poster Inviting Cancer Survivors to Provide Feedback on Study Findings 
 
 
                                                             
 
 
 
 
My name is Aleksandra Szproch and I am a postgraduate student at the 
Department of Psychology in Maynooth University, supervised by Dr Rebecca 
Maguire.  
As part of my MSc research, I 
conducted two studies investigating the 
experience of regret felt by cancer patients 
and survivors following decisions over 
treatment. These studies aimed to find what 
factors are most associated with regret in 
oncology populations.  
I am looking to present the findings of my research to cancer survivors 
and get some feedback or thoughts on what they mean to those living with or 
beyond cancer.  
Are you a cancer 
survivor living in Ireland? 
If so, we would value your help to interpret our 
research findings which relate to the experience of 
regret following cancer treatment decisions. 
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Study 1: Systematic Review of Existing Research 
The first study conducted was a systematic review of existing research– this involved 
searching databases to find published studies concerned with regret in cancer patients and 
survivors internationally. Appropriate studies were collected and analysed to find exactly 
what factors have been found to be associated with regret in oncology populations. Those 
factors were later grouped into five categories according to their nature: 
1. Sociodemographic factors (e.g., age, sex, income, etc.). We found that more treatment 
regret was reported by cancer patients who were not married, had lower education, 
were not white, had a lower income or experienced greater financial difficulty. 
2. The treatment chosen. Survivors of various cancers reported regret associated with 
various treatment types – there was no clear pattern found here. This finding suggests 
that decisions over any cancer treatment can elicit regret. 
3. Physical wellbeing. Patients and survivors who reported poorer physical wellbeing 
also reported higher levels of treatment regret. This included poor physical wellbeing 
due to the illness and the side effects of the chosen cancer treatment. 
4. The treatment decision making process. We found that the process in which the 
treatment decision is made has an impact on patient and survivor regret. Results 
showed that individuals mostly regretted not being involved enough in their treatment 
decision, not feeling informed enough about the decision they were making or that 
they were not informed about the side effects of the treatment. 
5. Psychological wellbeing and social support. Results showed more regret in patients 
with poor psychological wellbeing and in those who received little social support.  
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Study 2: Questionnaire examining experiences of cancer survivors in Ireland 
A limitation of study 1 is that findings may not apply to Irish cancer survivors. It also tended 
to focus on specific cancer types only. As part of the second study, I designed a questionnaire 
aimed at all Irish cancer survivors in order to gain insight into their decision-making 
experiences, their levels of treatment regret and the factors associated with their regret. Based 
on the responses of 92 survivors (mainly breast and prostate cancer survivors), three main 
factors were found to be associated with regret:  
1. Quality of life (both physical and psychological wellbeing). Irish cancer survivors 
were less likely to report regret if they felt they had higher levels of physical and 
psychological wellbeing. 
2. Shared-decision making (when the treatment decision is made by both the doctor and 
the patient). Survivors who reported that they took part in a shared-decision making 
strategy when deciding on their cancer treatment reported lower levels of regret. 
3. Resilience (the ability to cope well in adverse situations). Survivors with more 
resilience reported lower levels of regret. 
Overall regret levels were low and survivors reported a range of experiences, both positive 
and negative relating to their cancer decision making and the support provided to them. 
While females experienced greater regret than males, this difference may be due to overall 
differences in wellbeing between males and females. 
 
 
 
 
If you have any opinion on the findings of my project, or feel that these results 
have missed out on some aspect of regret in survivorship, please let me know 
by emailing me at aleksandra.szproch.2016@mumail.ie or by clicking on the 
link below. PPI (Public and Patient Involvement) is important in ensuring that 
these findings have relevance for cancer survivors. 
Click on or copy the following link to provide your feedback: 
https://maynoothpsychology.eu.qualtrics.com/jfe/form/SV_3HKYO7rfXsOYTt3  
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Research poster presented at the Psychology, Health and Medicine Conference 2020 
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Appendix I: Feedback Questionnaire for Cancer Survivors 
Exploring decision making and regret in cancer survivors - call for PPI input  
My name is Aleksandra Szproch and I am a postgraduate student at the Department of 
Psychology in Maynooth University, supervised by Dr Rebecca Maguire.  As part of my MSc 
research, I conducted two studies investigating the experience of regret felt by cancer patients 
and survivors following decisions over treatment. These studies aimed to find what factors 
are most associated with regret in oncology populations. I would love to present the findings 
of my research to cancer survivors and get some feedback or thoughts on what these mean for 
those living with or beyond cancer.  
Below is a description of our research followed by some questions.  
Study 1: Systematic Review of Existing Research 
The first study conducted was a systematic review of existing research– this involved 
searching databases to find published studies concerned with regret in cancer patients and 
survivors internationally. Appropriate studies were collected and analysed to find exactly 
what factors have been found to be associated with regret in oncology populations. Those 
factors were later grouped into five categories according to their nature:  
1.      Sociodemographic factors (e.g., age, sex, income, etc.). We found that more treatment 
regret was reported by cancer patients who were not married, had lower education, were not 
white, had a lower income or experienced greater financial difficulty. 
2.      The treatment chosen. Survivors of various cancers reported regret associated with 
various treatment types – there was no clear pattern found here. This finding suggests that 
decisions over any cancer treatment can elicit regret. 
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3.      Physical wellbeing. Patients and survivors who reported poorer physical wellbeing also 
reported higher levels of treatment regret. This included poor physical wellbeing due to the 
illness and the side effects of the chosen cancer treatment. 
4.      The treatment decision making process. We found that the process in which the 
treatment decision is made has an impact on patient and survivor regret. Results showed that 
individuals mostly regretted not being involved enough in their treatment decision, not 
feeling informed enough about the decision they were making or that they were not informed 
about the side effects of the treatment.  
5.      Psychological wellbeing and social support. Results showed more regret in patients 
with poor psychological wellbeing and in those who received little social support. 
Study 2: Questionnaire examining experiences of cancer survivors in Ireland 
A limitation of study 1 is that findings may not apply to Irish cancer survivors. It also tended 
to focus on specific cancer types only. As part of the second study, I designed a questionnaire 
aimed at all Irish cancer survivors in order to gain insight into their decision-making 
experiences, their levels of treatment regret and the factors associated with their regret. Based 
on the responses of 92 survivors (mainly breast and prostate cancer survivors), three main 
factors were found to be associated with regret: 
1.      Quality of life (both physical and psychological wellbeing). Irish cancer survivors were 
less likely to report regret if they felt they had higher levels of physical and psychological 
wellbeing. 
 2.      Shared-decision making (when the treatment decision is made by both the doctor and 
the patient). Survivors who reported that they took part in a shared-decision making strategy 
when deciding on their cancer treatment reported lower levels of regret. 
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3.      Resilience (the ability to cope well in adverse situations). Survivors with more 
resilience reported lower levels of regret.  
Overall regret levels were low and survivors reported a range of experiences, both positive 
and negative relating to their cancer decision making and the support provided to them. 
While females experienced greater regret than males, this difference may be due to overall 
differences in wellbeing between males and females. 
If you have any opinion on the findings of these two studies or feel that the results have 
missed out on an important aspect of cancer survivorship, please let us know below or 
email your feedback directly to aleksandra.szproch.2016@mumail.ie. 
If you have any opinions on the findings of this project, please comment on these below. 
Q1. Is there any aspect of cancer survivorship, especially in relation to regret, that may 
have been missed in this study? 
___________________________________________________________________________ 
Q2. Do you relate to the findings of this study in any way? 
___________________________________________________________________________ 
Q3. Do you feel like these findings have any implications for the care of cancer 
survivors? If so, please comment on what these implications might be. 
___________________________________________________________________________ 
Q4. If there is anything else you would like to comment on, please do so below. 
___________________________________________________________________________ 
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Q5. Are you a cancer survivor? 
Yes ☐  No ☐ 
Q6. How would you describe your gender? 
Male    ☐   Female   ☐ 
I’m not sure/questioning ☐   Prefer not to say  ☐ 
Other (e.g. non-binary), please specify __________________ 
 
Q7. If you would like to, please include any other details about yourself which you feel 
are relevant to this study. 
___________________________________________________________________________ 
Q8. Do you give consent for your written feedback to be included in Aleksandra 
Szproch's MSc research thesis? 
Yes ☐  No ☐ 
